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ABSTRACT

Herpetic stromal keratitis (SK) is an immunopathological and tissue destructive
corneal lesion caused by herpes simplex virus (HSV) infection, which induces an
intense autoimmune inflammatory response and finally leads blindness.
Accumulating evidence using the murine model has shown that Th-1 phenotype
CD4+

T

cells

orchestrating

the

inflammation

mainly

contribute

the

immunopathological reaction in HSV-1 infected cornea. However, prior to CD4+ T
cell infiltration into corneal lesions, various innate immune cells recruit and produce
numerous inflammatory molecules into the corneal stroma. Interestingly, one
prominent event early in the pathogenesis of SK is neovascularization of the usually
avascular cornea. It is assumed that various angiogenic factors produced by
inflammatory cells trigger the onset of pathological angiogenesis and the newly
formed leaky blood vessels may assist corneal access of inflammatory cells
orchestrating herpetic SK. Accordingly, inhibition of unwanted angiogenesis in an
HSV infected cornea may moderate the pathologic process of SK lesions.
The first part (Part I) of this dissertation focuses on the understanding of
HSV-1 induced SK pathogenesis including how abnormal neovascularization is
generated after virus infection and how angiogenesis contributes the process of
disease. The other parts (Part II, III, IV) explore the use of different antiangiogenic
approaches as an effective therapeutic strategy for herpetic SK. Results in Part II
demonstrate that the use of vascular endothelial growth factor (VEGF) pathwayspecific siRNAs can efficiently knock down their target genes and consequently
inhibit HSV induced angiogenesis. Results of the third section (Part III) clarify the
iv

antiangiogenic role of IL-18 in the cornea. The data show that IL-18 down-regulates
the expression of VEGF and also controls the proliferation of activated endothelial
cells in inflammatory conditions. Furthermore, application of DNA encoding IL-18
into cornea diminished herpetic SK lesion severity. The final section (Part IV)
explores the utilization of a VEGF receptor-2 (VEGFR-2 or FLK-1) based DNA
vaccine to enhance immune response against endothelial cells expressing VEGFR-2.
HSV-1 infected mice receiving attenuated Salmonella typhimurium harboring
VEGFR-2 exhibited antiangiogenic response and reduced herpetic SK severity.
These effects appeared to be due to the ability of cytotoxic CD8+ T cells targeting
VEGFR-2 to control virus induced neovascularization.
In this study, experiments were designed to focus on controlling the
pathological angiogenesis in herpetic SK model. We hope that these approaches
may represent useful therapeutic strategies against neovascularization-related eye
diseases.
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Part I
Background and Overview
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INTRODUCTION
Virus infections contribute to the onset of several autoimmune diseases (1-3). One
of the autoimmune diseases involved in this category is herpetic stromal keratitis
(SK), a lesion of the eye triggered by herpes simplex virus - 1 (HSV-1) infection (1,
3, 4). It is known that a majority of the population is sero-positive for HSV (5), but
usually shows few symptoms. However, recurrent lesions on the face, or less
frequently occurring eye infections following reactivation of latent virus within the
trigeminal ganglion, have appeared under stressful or immunocompromised
conditions (6, 7). Although facial lesions are normally mild and quickly disappear,
the latter eye lesions may result in severe inflammation and ultimately vision loss
(7). Numerous studies have shown that lesions due to herpetic SK appear to be
mediated by infiltrating and autoreactive CD4+ T cells in the immune privileged
cornea after day 7 post infection (8, 9). However, strong inflammation and intensive
neovascularization sprouting from preexisting limbal vessels are detectable during
viral replicating early phase of SK. These observations implicate that early
inflammatory events and pathological angiogenesis may contribute the pathogenesis
of herpetic SK (10). This review focuses on understanding and discussion about the
close relationship between abnormal angiogenesis and pathogenesis of herpetic SK.

MURINE HERPETIC SK MODELS
Corneal inflammation and ulceration following ocular infection with HSV-1 is the
main cause of vision loss in humans (affecting 0.15% of the population) in the
developed countries (11). Primary ocular infection with HSV-1 isolated from the
infected tissue of herpetic SK patients leads to the development of herpetic SK in
2

some mice strains (BALB/c and A/J mice) (7, 12, 13). Consequently, the animal
model has proven to be highly effective for understanding the pathogenesis of
human herpetic SK, since the lesions involved in murine herpetic SK are clinically
and histopathologically similar to those of human patient (14). Since human
herpetic SK is typically caused by infection with reactivated latent HSV-1 (15),
some animal reactivation models have been used for SK studies (16). However, due
to the low incidence of SK lesions, and pathologic cellular events in reactivation
models similar to them in primary ocular infection models, primary infection
models have recently been used more extensively (17).

Inflammatory immune response to HSV-1 ocular infection
Primary ocular infection is performed by direct application of virus into a
scratched cornea epithelial layer of susceptible mouse strains. Once the virus
successfully infects epithelial cells, viral replication begins and induces mild
destruction of epithelial cells (18). Based on the data from tear film or eye swab
assays (Fig. 1), high virus titers are detectable for a few days and finally the
replication subsides by 6-7 days post infection (19). At this early period (pre-clinical
phase), the infection is characterized by the infiltration of activated inflammatory
cells (19). It is assumed that viral antigens and several chemoattractant molecules
released from damaged corneal tissue may induce the influx of these inflammatory
cells into the corneal stroma (20). The major inflammatory cell types that infiltrate
into cornea within 12 h post infection are polymorphonuclear leukocytes (PMN,
mainly neutrophils). Previous studies have suggested two major roles of initial
influx of PMN in the pathogenesis of herpetic SK (16, 19, 21). Firstly, it has been
3

assumed that PMN control the viral replication and subsequently have a defense
mechanism against HSV-1. The fact that depletion of PMN during early phase leads
to delayed viral clearance from infected eyes and brain, and activated PMN release
antiviral molecules including IFN-γ, TNF-α, and nitric oxide support the idea of
advantageous functions of PMN (22, 23). However, herpetic SK is less severe in the
absence of PMN (19), suggesting that PMN may contribute to the pathogenesis of
herpetic SK. Since it has is known that activated PMN produce various tissue
destructive enzymes

(24), chemoattractive chemokines (20, 25-27), and

proinflammatory cytokines (20, 28, 29), these stimulators may induce tissue
destructive inflammatory conditions possibly unmasking unknown auto-antigens
related to the immunopathology and subsequently increase herpetic SK severity. In
addition to influx of neutrophils, infiltration of CD11b+ and CD11C+ cells,
presumably macrophages (30) and dendritic cells (31, 32), respectively, are also
detectable in the SK cornea within 24 h post infection. It is unclear what the role of
these cell types is in SK pathogenesis, but it is assumed that the functions of
macrophages may be similar to those of neutrophils (as described previously).
The cellular events in the SK cornea at clinical phase (after day 7 post
infection) are characterized by huge influxes of T cells escaping from newly formed
leaky blood vessels in the stroma (9, 33). Since HSV-1 infected mice without T
cells do not develop herpetic SK (34), it is believed that T cells are the major cell
types inducing herpetic SK pathology. Our group and others have demonstrated that
herpetic SK results from Th1 type CD4+ T cells that secrete IFN-γ, TNF-α (35, 36),
and IL-2, but not IL-4 and IL-10 (37). Accordingly, treatment of animals with
neutralizing antibodies against IFN-γ or IL-2 and overexpression of Th2 type
4

cytokines, IL-4 or IL-10 significantly diminished herpetic SK (38). Furthermore, a
recent report suggested that regulation of CD4+ T cells with CD4+CD25+ regulatory
T cells in immunocompetent conditions controled herpetic SK (39-41). The
evidence indicates that Th1 type CD4+ T cell is responsible for inducing
immunopathogenesis of herpetic SK. Interestingly, a huge influx of PMN is again
observed in the SK cornea at this stage and is characterized by a typical biphasic
response.

HSV-1 INDUCED OCULAR NEOVASCULARIZATION
HSV-1 ocular infection results in an inflammatory T cell mediated corneal lesion
called herpetic SK (7). Although various inflammatory cellular events are involved
in the pathogenesis of SK (18), one of the prominent early events in the process of
SK is unwanted neovascularization of the normally avascular cornea (10). Newly
formed neovessels with high capillary density begin sprouting from the preexisting
limbal vessels within 48 h after HSV-1 infection. After this time point, sprouting
blood vessels become apparent, and finally reach to the center of ulcerative cornea
around day 20 post infection (Fig. 2). Although it remains unclear whether
induction of ocular angiogenesis is HSV-1 specific and which multiple molecules
are responsible for HSV induced angiogenesis, several recent findings indicate the
close relationship between inflammatory cellular events and uncontrolled
angiogenesis (42-44). Indeed, inhibiting the angiogenic process results in
diminished SK lesions (24, 43, 44). Therefore, it seems likely that the angiogenic
events may be an essential step in the pathogenesis of herpetic SK.

5

The mechanism and process of angiogenesis
Before and after birth, the formation of new blood vessels proceeds
physiologically via vascularization for the growth and maintenace of organ tissue
(45, 46). Blood vessels supply the oxygen and nutrients to each organ and are also
responsible for wound healing (47). Vascularization requires coordinated and
sequential steps. Three distinct types of vascularization have been suggested, which
are vasculogenesis, arteriogenesis, and angiogenesis (46). During embryonic stages,
new blood vessels are first formed by a process referred to as vasculogenesis (48).
Vasculogenesis consists of the differentiation of pluripotent endothelial cell
precursors to endothelial cells, which ultimately form primitive capillary plexuses
(46, 49) and the cardiovasulcr system. Following the process of vasculogenesis,
rapid proliferation of arterial collateral blood vessels occurs by a process of
arteriogenesis (50). These collateral blood vessels possess more complex structures
consisting of endothelial cells, smooth muscle cells and pericytes (46). Thus
vasculogenesis and arteriogenesis are physiological processes that do not occur in
the adult. Under the influence of pathologic stimulators, however, the distinct
process of blood vessel formation from pre-existing blood vessels in the adult
occurs and it is called angiogenesis (51). Angiogenesis is a complex process
consisting of endothelial cell proliferation and migration, proteolysis of extracellular
membrane, capillary tube formation, and remodeling of vascular wall (46, 47).
Under normal or infectious conditions, the process of angiogenesis is a necessary
step for wound healing (47), the female reproductive cycle (52), and ischemic
restoration (53). Although almost an angiogenesis resulting from pathologic
conditions is beneficial for the resolution of wounds and inflammation, there are
6

some instances in which unwanted angiogenesis induces detrimental effects (54-56).
The typical examples of the latter case are tumor angiogenesis and neovascular
related eye diseases. The hypothesis that angiogenesis is essential for tumor growth
was first proposed by Dr. Judah Folkman group (57, 58) and numerous studies have
demonstrated this hypothesis (59, 60). Furthermore, uncontrolled angiogenesis is
found in eye diseases including macular degeneration, diabetic retinopathy and
herpetic SK (61).

Release of angiogenic stimulators: angiokines
Angiogenic growth factors are produced from various cell types, such as
inflammatory or tumor cells in pathologic conditions (62). Numerous angiokines
have been discovered and reveal their distinct role in angiogenesis (63, 64). Almost
all angiokines can be divided into two types. The first type consists of the vascular
cell growth factors, including VEGFs (65), fibroblast growth factors (FGFs) (66),
and angiopoietin 2 (67). In general, once these growth factors bind each receptor of
the endothelial cells, signaling pathways such as MAPK and Akt are activated (68)
and subsequent signaling promotes endothelial cell proliferation, migration, survival,
and proteolytic activity (69). It is known that almost all vascular growth factors are
produced from activated tumor cells (70), inflammatory PMN (71), macrophages
(62), and activated endothelial cells (72). The second type of angiokines consists of
proinflammtory

molecules,

including

various

cytokines

and

chemokines.

Proinflammatory cytokines such as IL-1 (28, 29), IL-6 (20), IL-17 (73), M-CSF (74),
TGF-β (75), and TNF-α (76) released from various cell types directly induce
expression of growth factors including VEGF and FGF-2. Chemokines such as
7

monocyte chemoattractant factor-1 (MCP-1) (77), a potent chemoattractant of T
cells and monocytes, and macrophage inflammatory protein (MIP-2, CXCL1)(78), a
potent chemoattractant of neutrophils, also lead to the recruitment of inflammatory
cells producing angiogenic factors.

Activation of the endothelial cells and remodeling of neovessels
Angiokines released from inflammatory origin diffuse into the nearby tissues
and reach the quiescent endothelial cells of preexisting blood vessels. Once the
diffused angiokines bind to their specific receptors expressed on the endothelial
cells, these cells become activated and begin to produce new molecules including
proteolytic enzymes and angiogenic factors by autocrine fashion for remodeling of
the

extracellular

matrix

(ECM).

The

enzymes,

mainly

of

the

matrix

metalloproteinases (MMPs and tissue inhibitors of metalloproteinases (TIMPs))
family and plasminogen activators (such as urokinase plasminogen activator (uPA)
and its inhibitor, PAI-1) (79-81), degrade the underlying basement membrane
surrounding all preexisting blood vessels. Then activated endothelial cells begin to
proliferate and migrate through the dissolved holes into nearby tissue stroma.
During migration of endothelial cells, integrins are considered to positively regulate
the remodeling process of vascular cells (82). Integrins are endothelial cell surface
receptors and assist vascular cells to build new blood vessels (83, 84). The αvβ3
and αvβ5 integrins have been thought to help the formation of blood vessel since
antagonists against these integrins diminish pathological angiogenesis (82).
Furthermore, adhesion between integrin α4β1 of endothelial cells and VCAM-1 of
mural cells is required for blood vessel formation (85). However, one report
8

suggests that some integrins inhibit angiogenesis by suppressing VEGF signaling
dependent endothelial cell survival (82).

Stabilization of newly formed blood vessels
To become a functional vascular network, newly formed nascent vessels
require stabilization. The association of pericytes, extracellular matrix, and smooth
muscle cells with newly formed vessels inhibits angiogenesis through regulation of
endothelial activity and provides structural support. Platelet-derived growth factor
(PDGF)-BB has been considered to have roles in the stabilization of new blood
vessels, since it induces recruitment of PDGFR-β-positive mesenchymal progenitor
cells (82). Another molecule to tighten blood vessels is the Tie-2 receptor, which is
activated by angiopoietin-1 (82). Signaling between Tie-2 and angiopoietin-1
promotes the interaction between endothelial cells and mural cells (86).
Consequently, nascent blood vessels become durable and mature vessels after
stabilization.

Contribution of unwanted angiogenesis during the pathogenesis of herpetic SK
One prominent characteristic in the pathogenesis of herpetic SK involves
neovascularization of the normally avascular cornea. Angiogenic sprouting with
high capillary density from preexisting limbal vessels is evident by day 2 post
infection and subsequently thick and durable vessels grow and reach the central
cornea with ulceration by day 20 post infection. Most studies on herpetic SK have
focused on the issues of autoinflammatory cellular and molecular events, but
recently our group has questioned how ocular infection with HSV-1 induces
9

abnormal angiogenesis and how this process contributes the pathogenesis of
herpetic SK. Although it remains to be more defined, evidence from several
experiments demonstrates that multiple molecules are involved in HSV-1 induced
angiogenesis and abnormal angiogenesis seems to be a necessary step in herpetic
SK pathogenesis (10, 20, 22, 24, 28, 29).
Virus-induced diseases characterized by pathological angiogenesis have
been suggested, and their pathogenesis has been revealed by numerous research
efforts. HIV-1 Tat protein directly induces angiogenesis since the Tat arginine- and
lysine- rich sequence is similar to that of other angiogenic factors, such as VEGF,
and Tat specifically binds and activates the VEGFR-2 (87). Hepatitis B virus X
protein (HBx) of the hepatitis B virus (HBV) is strongly implicated in angiogenesis
during hepatocarcinogenesis through activation of hypoxia inducible factor-1 (HIF1a) (88). The G protein-coupled receptor oncogene (vGPCR) of the Kaposi's
sarcoma (KS) associated herpesvirus (KSHV) induces angiogenesis by VEGF
secretion and activation of the VEGFR-2 (88). Orf virus encodes a homolog (NZ2)
of the VEGF family of genes and it induces angiogenesis by binding to VEGFR-2
and neuropilin-1 (89). However, in the pathogenesis of herpetic SK, unlike some
other virus related to the induction of angiogenesis, HSV-1 replication itself is not
likely to directly induce angiogenesis since HSV-1 appears not to encode any
angiogenic protein. Accumulating evidence indicates that innate immune cells such
as neutrophils (PMN) and macrophages are responsible for inflammation and
ongoing angiogenesis in the pathogenesis of herpetic SK (62, 71) (Fig. 3). As
previously mentioned, these innate immune cells are observed in the
subconjunctival area within 12 h post infection and quickly infiltrate into the
10

stromal layer within 24 h post infection. Although the antiviral role of innate
inflammatory cells through IFN signaling may help for clearance of replicating
virus and phagocytosis of infected cells by innate immune cells can suppress viral
pathogenesis, activated neutrophils and macrophages produce enormous angiokines
such as proinflammatory cytokines, chemoattractant chemokines, and endothelial
cell growth factors. For example, FGF-2 (unpublished data) known as a classical
angiogenic factor and MMP-9 (24), one of the major tissue destructive enzymes, are
highly expressed in SK cornea and are believed to contribute HSV induced
angiogenesis. Among several angiokines, high levels of VEGF production, which is
a potent inducer of pathological angiogenesis, is evident in the cornea during all
periods of SK (10). VEGF mRNAs and proteins are detectable by 12 h and 24 h
post infection, respectively (10). Additional evidence shows that biphasic pattern of
PMN recruitment reflects the similar pattern of VEGF expression in the SK corneas
(10). Furthermore, corneal epithelial cells and stromal fibroblast cells including
keratocytes are also considered to be sources of VEGF (18). During the clinical
phase, the newly formed and higly permeable blood vessels still grow toward to the
center of cornea. At this stage, by several unidentified chemoattractants, bystander
CD4+ T cells reach the cornea by escaping from the blood stream into the stroma
through gaps between vascular endothelial cells. Since CD4+ T cells are responsible
for inducing severe autoimmune inflammatory responses in SK cornea, successful
infiltration of CD4+ T cells into the inflammatory cornea should be crucial event in
the pathogenesis of herpetic SK. Notably, new blood vessels act as a route for
CD4+ T cells to reach into the stromal area. These observations suggest that VEGF
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molecules may be a strong stimulator of HSV-1 induced angiogenesis and that
neovessels contribute to herpetic SK pathogenesis (Fig. 4).
The next question is what signals induce VEGF production in the SK cornea.
Infiltrated innate inflammatory cells may constitutively produce VEGF, but it is
conceivable that some bystander activators may also be involved in this process.
The first candidate as stimulator for VEGF is HSV-1 DNA, which was previously
suggested by our group (18). Implantation of pellets including HSV-1 DNA into
normal cornea induces angiogenesis by upregulation of VEGF expression. The
precise mechanisms by which HSV DNA induces VEGF expression were
demonstrated by in vitro and in vivo experiments. Sequence analysis of HSV-1
DNA revealed that HSV DNA has plenty of bioactive CpG motifs, and treatment of
these bio-active CpG motifs into macrophage cell lines stimulates VEGF expression.
Furthermore, similar to HSV-1 DNA, CpG pellet implantation induces angiogenesis
(18, 90), but methylated CpG implantation abrogates the angiogenic effects of
bioactive CpG motifs. Although detailed mechanisms of how CpG motifs stimulate
VEGF production are yet to be elucidated, interaction of CpG and TLR9, a specific
receptor for CpG, may induce a signal transduction through a Myd88 dependent or
independent pathway and subsequently activate various signal transcription factors
stimulating VEGF expression.
Additional stimulators for VEGF production may be various cytokines
produced by innate inflammatory cells under SK conditions. Accumulating
evidence suggests that some proinflammatory cytokines such as IL-1 (28, 29), IL-6
(20), IL-17 (91), and IL-23 (unpublished data) are highly overexpressed in the SK
cornea. A direct injection of IL-1 or IL-6 protein into normal corneal stroma induces
12

angiogenesis through upregulation of the VEGF molecule and blocking of IL-1 with
IL-1 receptor antagonist protein can reduce HSV-induced angiogenesis. Recently
some data regarding the role of IL-17 and IL-23 in herpetic SK indicates that
upregulated IL-17 by HSV infection directly induces VEGF expression (91) and IL23 indirectly stimulates VEGF through upregulation of IL-17 (unpublished data).
Some final possible candidates that induce angiogenesis in SK cornea are
chemokines that can attract innate inflammatory cells, since several chemokines
having E-L-R motifs are known to induce angiogenesis (92). In SK studies, MIP-2
(CXCL1) and MCP-1 (CCL2) are upregulated in the cornea following HSV-1
ocular infection (93). Although it has not yet been clearly defined whether
overexpression of MCP-1, a potent chemoattractant of T cells and monocytes, in the
SK cornea highly recruits inflammatory cells expressing its receptor (CCR2) and
induces angiogenesis, the role of this chemokine has been implicated in
inflammatory angiogenic response in brain and retinal diseases (94). Additionally, it
was reported that neutralization of MIP-2 significantly diminished the influx of
innate immune cells into the SK cornea (95). Further evidence is provided by the in
vivo study that MIP-2 induced angiogenesis is mediated by neutrophil-derived
VEGF-A (78). These examples indicate that several chemokines indirectly induce
angiogenesis by recruitment of inflammatory cells producing various angiokines.
Since the influx of various innate and adaptive immune cells to inflammatory
lesions is crucially mediated by chemoattractants, numerous uninvestigated and
unidentified chemokines may be involved in the herpetic SK pathogenesis.
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Role of VEGF family genes
Identification and activities of VEGF molecule
VEGF is a crucial regulator of physiological angiogenesis related to fetal
embryogenesis (96, 97) and the female reproductive system (98) as well as
pathological angiogenesis associated with tumor growth (99) and neovascular eye
diseases, such as age-related macular degeneration (100) and diabetic retinopathy
(101). In 1983, Senger et al. first purified a protein from a guinea pig tumor cell line,
which induces vascular permeability, which they named “tumor vascular
permeability factor” (VPF) (102). Six years later, Ferrara and Henzel isolated an
endothelial cell-specific mitogen from bovine pituitary follicular cells, which they
named “ vascular endothelial growth factor” (103). However, cDNA cloning of
VEGF and VPF revealed that both angiokines were the same molecule (65). The
finding of this molecule was innovative since VEGF induces both endothelial cell
proliferation and vascular permeability, which is unlikely in other angiokines (65).
For the last decade, numerous research efforts have been focused on this molecule
to define the biological and pathological role of it. It has been known that VEGF
(commonly referred to VEGF-A) belongs to a gene family including placenta
growth factor (PlGF), VEGF-B, C, and D (72). VEGF (VEGF-A) is considered to
be the major angiogenic stimulator of blood vessels, and VEGF-C and D has been
known as regulator of lymphangiogenesis. VEGF has four different isoforms,
having 121, 165, 189, and 206 amino acids, with VEGF165 being the predominant
isoform (72).
Activities of VEGF are multi-functional. The main function of VEGF is to
influence the fate of vascular systems. Once VEGF interacts with vascular
14

endothelial cells, they become activated and being the process of angiogenesis,
which includes the proliferation and migration of endothelial cells. In addition,
VEGF enhances the survival of endothelial cells through preventing apoptosis and
expressing the anti-apoptotic molecule Bcl-2, survivin, and A1 from endothelial
cells (104). Unlike other angiokines, VEGF induces vascular permeability and
leakage in inflammatory circumstances. It also induces vasodilation by endothelial
cell-derived nitric oxide (105). Secondly, VEGF has effects on non-endothelial cell
types. VEGF attracts monocytes by chemotactic fashion and controls survival of
hematopoietic stem cells, as well as bone marrow cells (106).

Interaction of VEGF with VEGF receptor tyrosine kinases
VEGF binding receptors are expressed in the cell surface of vascular
endothelial cells, as well as on bone marrow-derived cells (107). Three types of
receptors for VEGF were identified as VEGFR-1, VEGFR-2, and VEGFR-3 (72)
(Fig. 5). VEGF binds two related receptor tyrosine kinases (RTKs), VEGFR-1 and 2 that are normally expressed on the surface of blood vessel endothelial cells (72).
VEGFR-3 is not a receptor for VEGF, but it is for VEGF-C and-D and it is
restrictively expressed in lymphatic endothelial cells (108). Accumulating evidence
has revealed the role of each receptors signaling as a consequence of VEGF
interaction. Based on in vitro and in vivo results, VEGFR-2 has an important role in
pathological angiogenesis (72). Although both VEGFR-1 and -2 are expressed in
the endothelial cells under the physiological conditions, activated and proliferating
endothelial cells markedly upregulate the expression of VEGFR-2 (109). VEGFR-2
is the major receptor involved in the endothelial cells survival, mitogenic,
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angiogenic, and permeability of blood vessels (72). In contrast, VEGFR-1 mediates
the embryogenic development through release of growth factors, but is not involved
in mitogenic signaling in endothelial cells (72). VEGFR-1 binds not only VEGF-A
but also VEGF-B and PLGF (72). Interestingly, the soluble form of VEGFR-1 by an
alternative splicing inhibits VEGF activity through prevention of VEGF binding to
VEGFR-2 (110).

VEGF family genes in pathologic conditions
Several studies have implied that VEGF family genes are closely involved in
the pathogenesis of diseases related to uncontrolled angiogenesis. Most extensive
studies relating to angiogenesis have been done in the wide variety of tumor models
(57, 58). Tumor cells need a supply of enough oxygen as well as nutrition to survive
and proliferate (111). Tumor cells as well as tumor-associated stroma produce high
amounts of VEGF molecules and the released VEGF spreads and binds to its
receptors expressed by nearby vascular endothelial cells. Therefore, inhibition of
VEGF family genes by various antiangiogenic approaches has successfully
suppressed the growth and spread of tumor cells (57, 58, 111). The examples of
VEGF family gene inhibitors include antibodies against VEGF and VEGFR-2 (112),
antisense oligonucleotides (113), molecules inhibiting VEGFR-2 signal transduction
(114), and a soluble VEGFR-1 inhibiting VEGF activities (110).
Abnormal angiogenesis and vascular leakage caused by secondary effects
due to diabetes or age are a major cause of blindness worldwide. Intraocular
overexpression of VEGF molecules is observed in the coroidal neovascular
membrane from patients with age-related macular degeneration (100) or in the
16

aqueous and vitreous humor of the eyes of diabetes mellitus patients (101). In the
latter case, VEGF is strongly upregulated in the ischemic retina and it may leak and
accumulate in the aqueous humor of retinopathy patient.
Upregulation of VEGF molecule has been also implicated in inflammatory
disorders. Although VEGF inducing angiogenesis enhances the capacity of tissue
repair and wound healing, it also contributes to the tissue destructive inflammatory
responses. High levels of VEGF are found in the synovial fluid of rheumatoid
arthritis patients and VEGFR-1 signaling has an important role in the development
of inflammatory arthritis (101). Brain adema induced by focal cerebral ischemia is
also mediated by VEGF expression in the brain since hypoxia is a major stimulator
for VEGF expression (115). Furthermore, Bartonella bacilliformis infection causing
verruga peruana syndrome characterized by the development of hemangioma-like
lesions induces epidermal production of VEGF (116).

Antiangiogenic strategies and therapeutic implications
As previously described, angiogenesis is mediated by complicated processes,
including the involvement of various angiokines and the cells producing them.
Further, pathologic angiogenesis is also often caused by the same angiokines that
are responsible for physiologic angiogenesis. For example, the VEGF molecule is
either beneficial for ischemic peripheral vascular disease or has detrimental effects
for inflammatory areas and leads to VEGF-mediated ocular complications,
depending on the tissues applied (117). Therefore, the angiokine agonist-antagonist
paradox should be considered when designing therapeutic strategies against
neovascular disorders.
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In animal studies and human clinical trials, inhibition of angiokines
including VEGF family genes by a variety of approaches has resulted in suppression
of the progress of some neovascular diseases. Conventionally, application of
angiogenesis inhibitors, such as TNP-470 (synthetic analogue of fumagillin) (118)
or immunosuppressive drug rapamycine (119), and blocking antibody against
angiokines and their receptors (112) efficiently inhibits primary and metastatic
tumor growth by antiangiogenic effects. In addition, natural antiangiogenic
molecules including endostatin (120), IFN-α (121), IL-12 (122), and TIMP-1 (123)
have been shown their antiangiogenic effects in various experimental models.
Recently, previously unidentified natural molecules that have antiangiogenic
functions are being discovered and tested. Furthermore, knock-down of endogenous
target genes by the use of siRNAs (43, 124) or antisense oligonucleotides (125) has
been explored and these approaches are currently pending for future human trials.
Interestingly, recent studies have shown that, using immunological concepts,
immunization, targeting cells expressing angiokines and their receptors,
successfully induces immune responses against self antigens and can regulate
overgrowth of unwanted vessels in animal models (109, 126).
Since pathological angiogenesis occurs in lesions under complicated and
complex processes of molecular and cellular events, and each neovascular disease
has different stages of pathogenesis, strategies that target single molecule or that
applies a single treatment may not be sufficient to control angiogenesis. Some
evidence also have suggested that angiokines may be critical during the initial
angiogenic stages (127). Such notions should be considered important for the design
of experimental and clinical trials.
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CONCLUSION
Prophylactic or therapeutic approaches have been suggested for regression of
herpetic SK pathogenesis. For instance, corticosteroid (128) or antiviral treatment
could reduce disease progression in animal models. However, many other cellular
and molecular events that contribute to SK pathogenesis may become a future target
for herpetic SK therapy. Considering one of these contributors, production of
various angiokines is evident and subsequent crucial angiogenic steps are involved
in the whole disease processes of murine herpetic SK. Therefore, antiangiogenic
approaches may prove to be useful strategies to suppress the severity of herpetic SK.
We anticipate that understanding the various antiangiogenic approaches in murine
herpetic SK model may be helpful for the future design of therapeutic strategies
against neovascular related ocular diseases, including herpetic SK.

SPECIFIC AIMS AND RATIONALE
Studies in mouse models have revealed that pathogenesis of herpetic SK is mediated
by

complex

cellular

and

molecular

events.

Interestingly,

inflammatory

neovascularization in normally avascular cornea is prominent following HSV-1
infection. Although a large number of angiokines may be involved in SK
angiogenesis, VEGF, one of the key regulators of angiogenesis, has been suggested
as a critical contributor of HSV-induced angiogenesis. Therefore, to inhibit ocular
angiogenesis and consequent SK lesions, the studies described here have been
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aimed at evaluating the various antiangiogenic strategies which target VEGF family
genes.
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Figure 1. Principle cellular events in herpetic SK pathogenesis.
After primary HSV-1 ocular infection, highly replicating virus are detectable for a
few days and finally the replication subsides by 6-7 days post infection. At this
early period (pre-clinical phase), the infection is characterized by the infiltration of
activated inflammatory cells mainly PMN (neutrophils). The cellular events in the
SK cornea at clinical phase (after day 7 post infection) are characterized by a huge
influx of T cells escaping from newly formed leaky blood vessels in the stroma.
Interestingly, a huge influx of PMN is again observed in the SK cornea at this
stage. Biphasic invasion of PMN in the cornea appears to be the crucial event for
herpetic SK pathogenesis.
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Figure 2. New blood vessels formation in the corneal stroma following HSV-1
infection.
One of prominent events early in the process of SK is uncontrolled
neovascularization of the normally avascular cornea. Newly formed neovessels with
high capillary density begin sprouting from the preexisting limbal vessels within 48
h after HSV-1 infection. After this time point, sprouting blood vessels become
apparent, and they ultimately reach the center of ulcerative cornea around day 20
after virus infection. The neovessels (arrow) express CD31 (PECAM-1), which is a
typical molecule expressed in blood vessel endothelial cells.
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Day 2 after HSV-1 infection

Naïve cornea

Figure 3. Cellular candidates that induce angiogenesis in SK cornea.
Following HSV-1 ocular infection, inflammatory cells with various subtypes
infiltrate into the SK cornea. Among them, PMNs, mainly neutrophils, are the
predominant cells during both preclinical and clinical phases of herpetic SK. Gr-1
positive inflammatory cells (arrow) are observed in the SK cornea at day 2 after
HSV-1 infection.
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Figure 4. Schematic representation of neovascularization process in the cornea
following HSV-1 infection and its contribution to herpetic SK pathogenesis.
HSV-1 infection and replication in the corneal epithelial cell resulted in the
production of various cytokines and chemokines. These proinflammatory molecules
subsequently lead to recruitment of innate immune inflammatory cells within 24 h
post infection and also directly induce VEGF expression from the SK cornea.
Infiltrating inflammatory cells such as neutrophils and macrophages produce
enormous

numbers

of

angiokines

such

as

proinflammatory

cytokines,

chemoattractant chemokines, and endothelial cell growth factors, mainly VEGF.
Once the released angiokines reach the nearby preexisting blood vessels, it leads to
the activation and proliferation of endothelial cells, which build up the new blood
vessels. In the clinical phase, new blood vessels supply a route for CD4+ T cells,
which are responsible for inducing severe autoimmune responses, to infiltrate into
the stromal area.

Abbreviations: HSV-1, Herpes Simplex Virus-1; CpG, Cytosine phosphate Glycine;
IL, Interleukin; VEGF, Vascular Endothelial cell Growth Factor; bFGF, basic
Fibroblast Growth Factor; MMP-9, Matrix Metallo Proteinase 9
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Figure 5. Role of VEGF receptor tyrosine kinases.
VEGF receptors have seven immunoglobulin-like domains in the extracellular
domain and a single transmembrane region. VEGFR-1 and -2 are expressed on the
surface of vascular endothelial cells and VEGFR-3 is expressed in lymphatic
endothelial cells. Once VEGF binds to each receptor, the signaling roles of each
receptor tyrosine kinase work differently.
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Part II
Inhibition of Ocular Angiogenesis by siRNA
Targeting Vascular Endothelial Growth FactorPathway Genes; Therapeutic Strategy for
Herpetic Stromal Keratitis
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Research described in this chapter is a slightly modified version of an article
published in 2004 in The American Journal of Pathology by Bumseok Kim,
Qingquan Tang, Partha S. Biswas, Jun Xu, Raymond M. Schiffelers, Frank Y. Xie,
Aslam M. Ansari, Puthupparampil V. Scaria, Martin C. Woodle, Patrick Lu, and
Barry T. Rouse

Kim, B., Q. Tang, P. S. Biswas, J. Xu, R. M. Schiffelers, F. Y. Xie, A. M. Ansari,
P. V. Scaria, M. C. Woodle, P. Lu, and B. T. Rouse. 2004. Inhibition of ocular
angiogenesis by siRNA targeting vascular endothelial growth factor pathway
genes: therapeutic strategy for herpetic stromal keratitis. Am. J. Pathol. 165(6):
2177-85. Copyright 2004. The American Association of Pathologist, Inc.
In this chapter “we” and “our” refers to co-authors and me. My contributions in the
paper include (1) selection of the topic (2) data analysis and interpretation (3)
planning experiments (4) compiling and interpretation of the literature (5)
understanding how results fit with the literature (7) compilation of contributions
into one paper (8) providing structure to the paper (9) making graphs, figures and
tables (10) writing and editing.

ABSTRACT
Ocular neovascularization often results in vision impairment. Frequently vascular
endothelial cell growth factors (VEGF) are mainly responsible for the pathological
neovascularization as in the case in neovascularization induced by CpG
oligodeoxynucleotides (ODN) and herpes simplex virus (HSV) infection in this
report. siRNAs targeting either VEGFA, VEGFR1, 2 or a mix of the three were
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shown to significantly inhibit neovascularization induced by CpG when given
locally or systemically. The efficacy of systemic administration was facilitated by
the use of a polymer delivery vehicle. Additional experiments showed a significant
inhibitory effect of the siRNAs mix when given either locally or systemically in
vehicle against HSV induced angiogenesis as well as against lesions of stromal
keratitis (SK). These results indicate that the use of VEGF pathway-specific
siRNAs represents a useful therapy against neovascularization-related eye diseases.

INTRODUCTION
New and uncontrolled blood vessel development in the eye is a pivotal process in
the pathogenesis of several ocular neovascularization diseases, including herpes
simplex virus (HSV)-induced stromal keratitis (SK), diabetic retinopathy, and agerelated macular degeneration (1). These ocular diseases may finally cause
blindness and managing them therapeutically is problematic. With HSV, the
commonest infectious cause of vision impairment and blindness in the western
world (2), neovascularization of the avascular cornea represents an essential step
in its pathogenesis (3). Multiple molecules may be responsible for the HSVinduced angiogenesis and it remains unclear how the virus infection results in the
induction of angiogenic factors (4). Recently, we demonstrated that HSV DNA
which contains abundant potentially bioactive CpG-containing motifs (5, 6), can
induce the potent angiogenesis factor vascular endothelial growth factor (VEGF)
and that neutralization of VEGF with antibody minimized HSV-induced
angiogenesis (3). A convenient model was also established in which bioactive
CpG-containing oligodeoxynucleotides (ODN) were also shown to induce
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neovascularization via the induction of VEGF (7, 8). This model is employed in
the present study to evaluate the therapeutic potential of RNA interference (RNAi)
to suppress VEGF expression and responsiveness.
Gene silencing by RNAi represents a potential important approach for
therapy as well as a rapid and reliable tool for gene discovery or gene validation
(9). Currently, small interfereing RNA (siRNA) has received modest use in vivo
(10). To achieve high efficacy in siRNA-mediated therapy, it is critical not only to
choose the correct gene target and to design appropriate siRNAs, but more
importantly also to efficiently deliver siRNAs into specific tissues or cells in vivo
(11). A previous report from our group demonstrated that targeting the VEGF
protein and its receptor was a successful means of inhibiting neovascularization
associated with tumor growth (12). Other reports have also shown success using
siRNA to MMP-9 against tumor angiogenesis (13). In the present study, we have
used siRNA targeting the VEGF pathway and shown that this system significantly
inhibits ocular angiogenesis induced by bioactive CpG and HSV infection. The
results of these studies have implication for the control of HSV induced vision loss.

MATERIALS AND METHODS
Reagents
Phosphorothioate ODNs were kindly provided by Dennis M. Klinman (Biologics
Evaluation and Research, FDA, U.S.A.). The sequences of stimulatory ODNs used
in this study were: 1466, TCAACGTTGA, and 1555, GCTAGACGTTAGCGT.
Subsequent studies were performed using an equimolar mixture of ODNs 1466
and 1555.
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Molecular design of gene targets and siRNAs
Three mVEGF pathway factors, mVEGF A and two mVEGF receptors
(mVEGFR1 and 2), were targeted by RNAi. For each gene target, two target
sequences were assigned at different locations on the same mRNA. siRNAs were
designed correspondent to the above target sequences. These siRNAs were
designed according to the guideline proposed by Tuschl’s group (14, 15). The
designed siRNAs (duplexes of sense and antisense strands) were synthesized by
Qiagen (Valencia, CA). All siRNAs were 21-nt long double stranded RNA oligos
with 2-nt (TT) overhang at 3’ end. The targeted sequences of mVEGFA were (a)
AAGCCGTCCTGTGTGCCGCTG and (b) AACGATGAAGCCCTGGAGTGC.
The targeted sequences of mVEGFR1 were (a) AAGTTAAAAGTGCCTGAACTG and (b) AAGCAGGCCAGACTCTCTTTC. The targeted sequences of
mVEGFR2 were (a) AAGCTCAGCACACAGAAAGAC and (b) AATGCGGCGGTGGTGACAGTA. The synthesis of unrelated siRNA controls, two target
sequences each for LacZ and firefly luciferase were used. They were LacZ (a)
AACAGTTGCGCAGCCTGAATG and (b) AACTTAATCGCCTTGCAGCAC,
Luc (a) AAGCTATGAAACGATATGGGC and (b) AACCGCTGGAGAGCAACTGCA. Subsequent studies were conducted using an equimolar mixture of (a)
and (b) for individual siRNA.

Mice
Female BALB/c mice (H-2d), 5 to 6 weeks old, were purchased from Harlan
Sprague-Dawley (Indianapolis, Ind.) and housed conventionally. All investigations
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followed guidelines of the Committee on the Care of Laboratory Animals
Resources, Commission of Life Sciences, National Research Council. The animal
facilities of the University of Tennessee (Knoxville) are fully accredited by the
American Association of Laboratory Animal Care.

Virus
HSV-l strain RE (kindly provided by Dr. Robert Lausch, University of Alabama,
Mobile) was used in all the procedures. Virus was grown in Vero cell monolayers
(American Type Culture Collection, Manassas, VA; Cat. no. CCL81), titrated, and
stored in aliquots at -80°C until used.

In vitro efficacy of siRNA
To test the efficacy of RNAi in vitro, the following cell lines were used.
RAW264.7 gamma NO (-) cells (ATCC, CRL-2278) were used to test the
efficiency of siVEGFA specific knockdown of VEGFA gene that is spontaneously
expressed in these cells. The cells were plated in a 6 well plate in RPMI with 10%
FBS overnight at 37°C in 5% CO2. One day after cell plating, the cells were
transfected with different concentrations of siVEGFA or siLuc (at 0, 0.1, 0.5, 1.0,
or 2.0 µg/2 ml/well, respectively) using Lipofectamine 2000 (Invitrogen, Carlsbad,
CA). Twenty four hours later RNA from these cells was extracted for RT-PCR to
detect VEGF (see RNA Extraction and RT-PCR).
SVR cells (ATCC, CRL-2280) were used to test the efficiency of
siVEGFR1 specific knockdown of VEGFR1 gene that is constitutively expressed
on these cells. The cells were plated in a 6 well plate in DMEM with 5% FBS
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overnight at 37°C in 5% CO2. One day after cell plating, the cells were transfected
with different concentrations of siVEGFR1 or siLuc (at 0, 0.1, 0.5, or 1.0 µg/2
ml/well, respectively) using Lipofectamine 2000. Forty eight hours later RNA
from these cells was extracted for RS-PCR to detect VEGFR1 (see RNA
Extraction and RS-PCR).
293 cells (ATCC, CRL-1573) were used to transfect with mVEGFR2expressing plasmid for the detection of knockdown of exogenous mVEGFR2. The
cells were plated in a 6 well plate in DMEM with 5% FBS overnight at 37°C in
5% CO2. One day after cell plating, the cells were cotransfected with plasmid pCIVEGFR2 (0.2 µg/2 ml/well) and siVEGFR2 [a, b, a+b], or siLuc (0, 0.1, 0.5, or
1.0 µg/well, respectively) using Lipofectamine 2000. Forty eight hours later RNA
from these cells was extracted for RS-PCR to detect VEGFR2 (see RNA
Extraction and RS-PCR).

RNA Extraction and RT or RS-PCR
At various time points following siRNA treatment, the cells were harvested and
RNA was extracted by using RNeasy protect mini kit (Qiagen, Valencia, CA). In
case of ocular infection, 2 corneas/time point were excised and transferred to
RNAlaterTM. Briefly, cells were lysed in RLT buffer (Qiagen, catalog no. 79216)
and RNA was purified according to manufacturer’s instructions. RNase-free Dnase
set (Qiagen) was used to remove any contaminating genomic DNA. Total cellular
RNA (10 µg/ml) was reversed-transcribed using oligo (dT) primers and reverse
transcriptase (Promega, Madison, WI), according to protocols described previously
(16). The cDNA was made by the reverse-transcription reaction incubated at 42°C
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for 90 min. The primer sequences for mVEGF RT-PCR were: 5’GCGGGCTGCCTCGCAGTC-3’ (sense) and 5’-TCACCGCCTTGGCTTGTCAC3’ (antisense). RT-PCR products were 644 bp for mVEGF164 and 512 bp for
mVEGF120. The amplification profile was 94°C for 1 min, 65°C for 1 min, and
72°C for 15 min for 30 cycles. The PCR products were separated by 1% agarose
gel electrophoresis.
The RS-PCR was also performed for detection of mRNA knockdown by
siRNAs in vitro. Cytoplasmic RNA was isolated by RNAwiz (Ambion, #9736)
according to manufacturer’s instruction with additional DNAse treatment, and
subjected to RS-PCR with specially designed primers. The mRNA-specific reverse
primers for the RT reaction were all 47-mer oligos with the 5’-end 30-mer of
unique sequence (called “TS1” sequence, indicated in uppercase below) linked to a
17-mer sequence unique for each mRNA molecule (in lower case below). They
were (from 5’ to 3’): 1) mVEGFR1 dn: GAACATCGATGACAAGCTTAGGTATCGATAtagattgaagattccgc: 2) mVEGFR2dn: GAACATCGATGACAAGCTTAGGTATCGATAggtcactgacagaggcg. The PCR assays for all the tested
genes, that follow the RT assay, used a same reverse primer, TS1:
GAACATCGATGACAAGCTTAGGTATCGATA. The forward primers for PCR
were all 30-mer oligos, unique for each gene: mVEGFR1up: GTCAGCTGCTGGGACACCGCGGTCTTGCCT and mVEGFR2up: GGCGCTGCTAGCTGTCGCTCTGTGGTTCTG. The RT-PCR of housekeeping gene GAPDH was used as
control for RNA amount used in RS-PCR. An oligo dT primer (19-mer) was used
for RT assay of GAPDH. The primers used for the followed PCR were 20-mer
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oligos: 1) GAPDHup: CCTGGTCACCAGGGCTGCTT; 2) GAPDHdn: CCAGCCTTCTCCATGGTGGT.

Corneal micropocket Assay
The corneal micropocket assay used in this study observed the general protocol of
Kenyon et al. (17). Pellets for insertion into the cornea were made by combining
known amounts of CpG ODNs, sucralfate (10 mg, Bulch Meditec), and hydron
polymer in ethanol (120 mg/1ml ethanol, Interferon Sciences), and applying the
mixture to a 15×15 mm2 piece of synthetic mesh (Tekto). The mixture was
allowed to air dry and fibers of the mesh were pulled apart, yielding pellets
containing 1 µg of CpG ODNs. The micropocket was made around 1 mm from the
limbus under a stereomicroscope (Leica Microsytems, Wetzlar, Germany) (four
eyes per group) and pellets containing CpG ODNs were inserted into the
micropocket.
Angiogenesis was evaluated at day 4 and 7 after pellet implantation by
using calipers (Biomedical research instruments, Rockville, Maryland) with a
stereomicroscope. The length of the neovessels originated from the limbal vessel
ring toward the center of the cornea and the width of the neovessels presented in
clock hours were measured (4). Each clock hours is equal to 30˚ at the
circumstance. The angiogenic area was calculated according to the formula for an
ellipse. A = [(clock hours) × 0.4 × (vessel length in mm) × π] / 2.
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In vivo delivery of siRNA
For local delivery, siRNA (10 µg/10 µl per eye) was diluted in PBS and delivered
subconjunctivally. The subconjunctival injections were given by a 32-gauge
hamilton syringe (Hamilton company, Reno, Nevada) at 6 and 24 h after CpG
pellets implantation or day 1 and 3 after virus infection under deep anesthesia
induced by Avertin (Pittman Moore, Mondelein, IL). siRNA was injected 2 mm
behind the limbus. For systemic injection, siRNA (40 µg/100 µl per mice) was
mixed with polymer (TargeTran) and delivered intravenously. The tail vein
injections were given at 6 and 24 h after CpG pellets implantation or day 1 and 3
after virus infection using a 32-gauge syringe.

Corneal HSV-1 infection
Corneal infections of all mouse groups were conducted under deep anesthesia
induced by Avertin. The mice were scarified lightly on their corneas with a 30gauge needle, and a 2µl drop containing 1 x 105 plaque-forming units (PFU) of
HSV-1 RE was applied to the eye and gently massaged with the eyelids (six mice
per group).

Clinical observations (HSK severity and angiogenic scoring)
The eyes were examined on different days after infection for the development of
clinical lesions by slit-lamp biomicroscopy (Kawa Company, Nagoya, Japan), and
the clinical severity of keratitis of individually scored mice was recorded. The
scoring system was as follows: 0, normal cornea; +1, mild corneal haze; +2,
moderate corneal opacity or scarring; +3, severe corneal opacity but iris visible; +4,
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opaque cornea and corneal ulcer; +5, corneal rupture and necrotizing stromal
keratitis. The severity of angiogenesis was recorded as described previously (4).
Briefly, a grade of 4 for a given quadrant of the circle represents a centripetal
growth of 1.5 mm toward the corneal center. The score of the four quadrants of the
eye were then summed to derive the neovascularization index (range 0–16) for
each eye at a given time point (4).

Quantitative real-time PCR
Total cellular RNA was isolated from two corneas at day 7 p.i. using RNeasy RNA
extraction kit (Qiagen, Valencia, CA) according to manufacturer’s protocol.
DNase treatment (Qiagen, CA) was done to remove any contaminating genomic
DNA. To generate cDNA, 1 µg of total RNA was reverse transcribed using murine
leukemia virus reverse transcriptase (Gibco BRL Life Technologies, Bethesda,
MD) with oligo(dT) as primers (Invitrogen, CA). All cDNA samples were
aliquoted and stored at -20°C until further use.
Real-time PCR was performed using a DNA Engine Opticon (MJ Research
Inc.). PCR was performed using SYBR Green I reagent (Qiagen, Valencia, CA),
according to manufacturer’s protocol. During the optimization procedures of the
primers, 1% agarose gel analysis verified the amplification of one product of the
predicted size with no primer-dimer bands. The absence of primer-dimer formation
for each oligonucleotide set was also validated by establishing the melting curve
profile. The semiquantitative comparison between samples was calculated as
follows: the data were normalized by subtracting the difference of the threshold
cycles (CT) between the gene of interest’s CT and the “housekeeping” gene
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GAPDH’s CT (gene of interest CT – GAPDH CT = ∆CT) for each sample. The ∆CT
was then compared to the expression levels of the vector control sample (sample
∆CT – vector ∆CT). To determine the relative enhanced expression of the gene of
interest, the following calculation was made: fold change = 2(– sample ∆CT

– vector ∆CT)

.

The primers used were murine GAPDH sense, CATCCTGCACCACCAACTGCTTAG and antisense, GCCTGCTTCACCACCTTCTTGATG, and murine VEGF164 sense, GCCAGCACATAGAGAGAATGAGC and antisense, CAAGGCTCACAGTGATTTTCTGG.

VEGF quantification of corneal lysates by ELISA
The level of corneal VEGF protein expression was measured by a standard
sandwich enzyme-linked immunosorbent assay (ELISA) protocol. For preparation
of corneal lysates, two corneas/time point (n = 4) were collected and minced.
Minced pieces were collected in 1 ml of DMEM without FCS and homogenized
using ultra sonicater (Heat systems-Ultrasonics, NY, U.S.A.). The lysate was then
clarified by centrifugation at 12,000 rpm for 5 min at 4°C. The supernatant was
collected and stored at -80°C till further use.
The ELISA plate was coated with anti-mouse VEGF capture antibody (100
µl/well of the capture antibody at 0.4 µg/ml) and incubated at 4°C overnight. The
plate was washed with 0.05% tween20/PBS and blocked with 3% BSA for 2 h at
room temperature. After washing, serially diluted corneal lysates were added to the
plate and incubated at 4°C overnight. The plate was washed followed by antiVEGF biotinylated detection Ab (R&D system) for 2 h. Finally, peroxidaseconjugated streptavidin (Jackson ImmunoResearch Laboratory, PA, U.S.A.) was
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added. The color reaction was developed using ABTS (Sigma-Aldrich, St. Louis,
MO) and measured with an ELISA reader (Spectramax 340; Molecular Devices,
Sunnyvale, CA) at 405 nm. Quantification was performed with Spectramax ELISA
reader software version 1.2.

Statistical analysis
Significant differences between groups were evaluated by using the Student’s t test.
P < 0.05 was regarded as significant difference between the two groups.

RESULTS
Knockdown of VEGF-pathway genes by siRNA in vitro
Three individual siRNAs were developed. These were siVEGFA, siVEGFR1, and
siVEGFR2. Each was tested in a different cell system in vitro to measure its gene
silencing efficiency. The siVEGFA was tested in RAW NO (-) macrophage cells,
that produce VEGFA endogenously (18). Cells were transfected with siVEGFA, or
control siLuc siRNA at various doses, and RT-PCR was performed 24 h after
transfection. As shown is Fig. 1A, expression of both the 120 and 164 isoforms of
VEGF was reduced by siVEGFA, in a dose dependent manner. The efficacy of the
siVEGFR1 reagent was evaluated in SVR cells that endogenously express the
VEGF receptor 1 (19). As shown in Fig. 1B, VEGFR1 expression measured by
RS-PCR 48 h post transfection was diminished in a dose dependent manner
whereas all concentrations of the control siLuc siRNA resulted in similar levels of
VEGFR1 signal. Finally the siVEGFR2 reagent was tested in 293 cells that were
exogenously transfected with a plasmid encoding VEGFR2. To measure the
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silencing effect of siVEGFR2, a cotransfection approach using siVEGFR2 and
VEGFR2 DNA at various doses was performed. 293 cells were cotransfected with
various concentrations of siRNA targeting mVEGFR2 (0.1, 0.5, 1.0 µg/well) and
plasmid expressing mVEGFR2 (0.2 µg/well). RNA was isolated 48 h postcotransfection and exogenous expression of mVEGFR2 was measured by RS-PCR.
Fig. 1C shows that VEGFR2 expression was reduced by siVEGFR2, but not by the
control siRNA molecule. These results indicate that all the tested siRNAs were
able to suppress the targeted genes in vitro.

Inhibition of CpG-induced angiogenesis by local delivery of siRNAs targeting
VEGF-pathway genes
A previous study demonstrated that CpG containing ODN encapsulated in hydron
pellets induce VEGF mediated angiogenesis when inserted into corneal
micropockets (7). This system was used to measure the inhibitory effect of local
administration of siRNA preparations designed to target VEGF as well as two of
its receptors (VEGFR1 and 2). A single dose of 10 µg siRNA in PBS was used in
all cases. This was administered by subconjunctival injection 24 h after the
establishment of micropockets containing CpG ODN. The siRNAs were tested
individually as well as a 1:1:1 mixture of all three (siVEGFA, siVEGFR1 and
siVEGFR2). New blood vessel formation in the corneal limbus was monitored at
both day 4 and 7 after pellet implantation. As shown in Fig. 2, significant
inhibition of corneal neovascularization resulted with all three test siRNAs
compared to those given control siLacZ at day 4 after pellet implantation (p <
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0.05). The combination of the three tested siRNAs was the most effective inhibitor,
providing an approximately 60% reduction in neovascularization (p < 0.01).

Inhibition of CpG-induced neovascularization by systemic delivery of siRNAs
targeting VEGF-pathway genes
To test the anti-angiogenic effect of targeted individual siRNA and the efficiency
of systemic siRNA delivery, mice with CpG ODN-containing micropockets were
given a single dose i.v. of 40 µg siRNAs containing either siVEGFA, siVEGFR1,
siVEGFR2, a mix of the three, or control siLacZ 6 and 24 h post pellet
implantation. In these experiments a polymer (“Targetran”) was used that was
shown in previous studies on tumor angiogenesis to facilitate extravascular
delivery of siRNA (12). At day 4 and 7 after pellet implantation, the extent of
angiogenesis was measured. As shown in Fig. 3, all reagents used individually
induced significant inhibition of neovascularization compared to the siLacZ treated
group at day 4 after pellet implantation (p < 0.05). As observed with local
administration, the mix of the three test reagents provided the most effective
inhibition (average 40% inhibition, p < 0.01). In additional experiments, the
function of the polymer vehicle was evaluated by comparing the antineovascularization activity of the test mix suspended in polymer or given in PBS.
These experiments revealed that the use of the polymer vehicle resulted in more
effective anti-neovascularization than was evident when the PBS vehicle was used
although result was only significant at the early test period (p < 0.05) (Fig. 4A).
The results demonstrate that ocular neovascularization can be controlled by the i.v.
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administration of siRNA that target the VEGF system genes and that the use of the
“TargeTran” vehicle enhanced the efficacy of the therapeutic effect.
To determine the efficient anti-angiogenic dose of siRNA in systemic
delivery, mice with CpG ODN-containing micropockets were given a single dose
i.v. of 10, 20, 40, 80 µg siRNAs containing a mix of the siVEGFA, siVEGFR1 and
siVEGFR2, or control siLuc with TargeTran vehicle at 6 and 24 h post pellet
implantation. As shown in Fig 4B, administration of siRNAs inhibited CpG
induced angiogenesis in a dose dependent manner.

Therapeutic application of siRNAs against VEGF-pathway genes in the HSK
model
Previous studies have shown that VEGF is the critical angiogenic factor for
induction of HSV specific angiogenesis in the HSK model (3). To evaluate
whether administration of siRNAs targeting VEGF-pathway genes inhibits the
development of HSK, the corneas of mice were scarified and infected with 1× 105
HSV-1 RE. Then mice were given a single dose of 10 µg (subconjunctival
injection for local delivery) or 40 µg (tail vein injection for systemic delivery) mix
of siRNAs (an equimolar mixture of siVEGFA, siVEGFR1, and siVEGFR2) with
polymer vehicle at day 1 and 3 after virus infection. As shown in Fig. 5, the
angiogenesis and severity of HSK was significantly reduced in mice treated with
siRNAs targeting VEGF-pathway genes either locally or systemically compared to
animals treated with siLuc control (p < 0.05). Whilst 80% of siLuc control treated
eyes developed clinically evident lesions (score 2 or greater at day 10 p.i.), only
42% (local delivery) or 50% (systemic delivery) of eyes treated with siRNAs
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targeting VEGF-pathway genes developed such lesions. In addition by day 10 p.i.,
the angiogenesis score was greater than 6 in 9 of 12 control eyes, but only in 5 of
12 eyes of mice treated with siRNAs against VEGF-pathway genes by either local
or systemic delivery. Taken together these results show that administration of
siRNAs against VEGF-pathway genes reduced development of HSK via inhibition
of angiogenesis.

Decreased level of VEGF mRNA following treatment of siRNAs targeting
VEGF-pathway genes in HSV-1 infected cornea
To address whether treatment of siRNAs against VEGF-pathway genes reduces
the level of VEGF mRNA, corneas were collected at day 4 or 7 p.i. from mice that
5

were infected with 1×10 pfu HSV-1 RE and were treated with siRNAs targeting
VEGF-pathway genes at day 1 and 3 after viral infection. The VEGF mRNA level
was measured by RT-PCR or quantitative real-time PCR. As shown in Fig. 6A, the
expression of VEGF mRNA was reduced in the cornea treated with siRNAs
against VEGF-pathway genes compared to control eye at day 4 and 7 post
infection. In addition, similar to what is found in RT-PCR, cornea treated with
siRNAs against VEGF-pathway genes showed the significant reduction in VEGF
gene expression in comparison to cornea treated with siLuc control at 7 day
p.i.(Fig. 6B).
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Decreased VEGF protein levels following application of siRNAs against VEGFpathway genes in HSV-1 infected cornea
To evaluate whether treatment of siRNAs targeting VEGF-pathway genes
diminishes the production of VEGF protein, we measured VEGF protein in HSV-1
infected and siRNAs treated cornea at day 7 after infection. As shown in Fig.7,
VEGF protein levels were lower in those that received siRNAs targeting VEGFpathway genes compared to controls given siLuc with polymer (p < 0.05). Once
again administration of siRNA targeting VEGF-pathway with polymer inhibited
the production of its target gene in the HSK cornea.

DISCUSSION
This study was undertaken to determine if siRNAs targeting VEGF and VEGF
receptors gene expression could effectively inhibit ocular vascularization. To
measure the effect, angiogenesis was induced by inserting bioactive CpG into
corneal micropockets, a system that may model the mechanism by which HSV-1
induces neovascularization and ultimately blindness (2, 7, 17). Our results show
that siRNA administered either locally or administered systemically had
significant inhibitory effects on the neovascularization. Whereas individual siRNA
targeted against VEGF or either of its two receptors had activity, maximal effects
were observed when a 1:1:1 mix of the three siRNAs was used. Local
administration to the conjunctiva was observed to result in the best therapeutic
effect, but i.v. administration, especially when administered in the polymer vehicle
“TargeTran”, was almost as effective. Additional experiments showed that the
siRNA mixture given i.v. diminished VEGF protein levels in the HSV-1 infected
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cornea. The approach holds promise as a means to control ocular
neovascularization, a pathological event in several ocular diseases.
Gene silencing by RNA interference has been well demonstrated to
efficiently knockdown targeted genes in vitro, but few reports describe similar
effects in vivo. One of the important factors for its reliability in vivo may be the
delivery and transfection efficiency of siRNAs. However the efficiency of RNAi
delivery systems in mammalian cells is still low (20, 21). Based on previous
reports, systemic delivery of siRNAs by tail vein injection could not efficiently
deliver their siRNAs to their target areas because siRNA molecules are easily
trapped in the non-specific organs including liver, lungs, and spleen (11, 22). The
use of the polymer “TargeTran” may facilitate the delivery of contained reagents
at inflammatory neovascular sites. Using a FITC-labeled siRNA system we could
demonstrate signals in the neovascular bed that were appreciably greater than
observed when the labeled siRNA was administered in PBS (Fig. 8). This polymer
is composed of b-polyethylene imine (bPEi), polyethylene glycol (PEG), and
arginine-glycine- aspartate peptide sequences (RGD) (23, 24) (Fig. 9). bPEi binds
to negative charges in phosphates of the siRNA. RGD motif has been identified as
an integrin ligand of activated endothelial cells (25). Endothelial cells express a
number of different integrins and integrin αvβ3 and α5β1 have been shown to be
important during angiogenesis (25, 26). Both integrins are the receptor for matrix
proteins with an exposed RGD tripeptide moiety and are most prominent on
cytokine-activated endothelial cells during angiogenesis (25). Therefore in this
study, we targeted the RGD specific integrins on activated and proliferating
endothelial cells for siRNA delivery. Our systemic delivery study showed that the
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angiogenic inhibitory efficiency of siRNAs with polymer was higher than that of
siRNAs without polymer. In addition, we did not observe any abnormalities in
mice that experienced systemic delivery of siRNAs with either polymer or PBS at
least until the end of the experiment at 21 days after virus infection and siRNA
treatment although VEGF pathway genes are necessary for physiological events.
Because the half-life of siRNA molecules is short in serum, we believe not only
that our siRNAs with polymer can specifically reach in the inflammatory area
within short time, but also that the dosage of our siRNAs is not toxic concentration
in the mouse treated with siRNAs systemically.
Ocular neovascularization is abnormal proliferation and migration of new
blood vessels from preexisting vessel in the eye. Cornea is the avascular organ in
normal eye (27). However, if the cornea is infected or stimulated by angiogenic
factors, the development of new blood vessels starts from the vessel of limbal area
and new formed blood vessels reach on the top of the cornea (28). This
neovascularization in the cornea supports the recruitment of inflammatory cells to
the corneal tissue. These recruited inflammatory cells, especially neutrophils,
produce many angiogenic factors such as VEGF and then these angiogenic factors
induce angiogenesis and finally cause blindness. One of the diseases that show
severe angiogenesis in the cornea is the herpetic stromal keratitis (HSK) induced
by herpes simplex virus 1 (HSV-1) (3). Recent several studies show that
potentially bioactive CpG-containing motifs of HSV DNA could stimulate cells to
produce VEGF and induce angiogenesis in the eye (7, 8). In addition, strong
induction of VEGF expression was found in several neovascularized eye diseases.
For these reasons, we designed our experiment using CpG ODN as angiogenic
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stimulator and siRNA against VEGF and its receptors as angiogenic inhibitor for
the eye disease model.
In conclusion, using nanoparticle polymer systems, we delivered siRNA
duplexes targeting VEGF pathway genes to inhibit the CpG ODN induced corneal
neovascularization with a mouse model. The significant inhibition of the CpGinduced angiogenesis observed in the study strongly suggested that siRNA-mediated
anti-angiogenesis effect represents a potential therapeutic for several uncontrolled
angiogenesis diseases. In addition administration of siRNA duplexes targeting
VEGF pathway significantly inhibits development of HSK. This present observation
demonstrates that the use of VEGF pathway-specific siRNAs with clinically
feasible delivery system holds great potential as a novel therapeutic for
neovascularized eye diseases. It may also apply to other neovascularization-related
eye diseases, including diabetic retinopathy and age-related macular degeneration.
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Figure 1. siRNA-mediated in vitro knockdown of VEGF-pathway genes.
RAW264.7 NO (-) cells (A) and SVR cells (B) in 35mm wells were transfected
with siRNA (equimolar mixture of two targeted sequences a + b) targeting
mVEGFA and mVEGFR1, respectively, at the amount indicated. 293 cells (C)
were cotransfected with siRNA targeting mVEGFR2 (equimolar mixture of two
targeted sequences a+b was used in subsequent experiments) and plasmid
expressing mVEGFR2 at the amount indicated. Cellular RNA was isolated 24h
(RT-PCR) or 48 h (RS-PCR) post-transfection, and the knockdown of endogenous
expression of mVEGFA or mVEGFR1, or exogenous expression of mVEGFR2
was measured by RT-PCR for mVEGFA, or RS-PCR for mVEGFR1 and
mVEGFR2.
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Figure 2. Local delivery of siRNAs targeting VEGF-pathway genes inhibits the
CpG ODN- induced angiogenesis.
24 h after implantation with CpG ODN (1 µg) into the micropocket in mouse
cornea, mouse was given 10 µg per eye of siLacZ, siVEGFA, siVEGFR1,
siVEGFR2, or siVEGFmix (an equimolar mixture of total siRNAs targeting
VEGF-pathway genes) by subconjunctival injection. The angiogenesis area was
measured on day 4 and 7 after the CpG pellets implantation (four mice per group).
Statistically significant differences in angiogenic areas (* p < 0.05, ** p < 0.01)
were observed between the groups (A). Images were taken by stereomicroscopic
imaging system at days 7 after CpG pellets implantation (original magnification,
x40)(B).
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Figure 3. Systemic delivery of siRNAs against VEGF-pathway genes inhibits the
CpG ODN- induced angiogenesis.
Individual siRNAs or a mixture of total siRNAs against VEGF-pathway genes
were delivered with TargeTran, 6 and 24 h after the CpG ODN induction by tail
vein injection. The angiogenesis area was measured on day 4 and 7 after the CpG
pellets implantation (four mice per group). Statistically significant differences in
angiogenic areas (* p < 0.05, ** p < 0.01) were observed between the groups (A).
Images were taken by stereomicroscopic imaging system at days 7 after CpG
pellets implantation (original magnification, x 40) (B).
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Figure 4. Increased efficiency of siRNAs systemic delivery by polymer and dose
response experiment.
A mixture of siVEGF-pathway genes or siLuc control (40 µg) with polymer or
PBS control was delivered 6 and 24 h after the CpG ODN induction. The
angiogenesis area was measured on day 4 and 7 after the CpG pellets implantation
(four mice per group). Statistically significant differences in angiogenic areas (* p
< 0.05) were observed between the groups (A). Dose response (10, 20, 40, 80 µg
siRNAs) experiment with mixed siRNAs targeting VEGF-pathway genes with
polymer in the systemic delivery system was performed. The angiogenesis area in
each of the four mice for each group was measured on day 4 and 7 post
implantation of CpG ODN, and the anti-angiogenic efficiency was compared
between different siRNA dosages (B).
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Figure 5. Reduced HSK severity and angiogenic response by administration of
siRNAs targeting VEGF-pathway genes.
5

Mice were infected with 1×10 PFU HSV-1 RE per eye, and at day 1 and 3 p.i.,
were treated with siVEGF mix or siLuc with polymer either local or systemically.
Mean lesion HSK score (A) and angiogenic score (B) were calculated at day 10
after viral infection. Each dot represents the clinical score for one eye. Horizontal
bars and figures in the parenthesis indicate the mean for each group. Data is
complied from two separate experiments consisting of 6 eyes in each group. *
Statistically significant differences in HSK or angiogenesis score (p < 0.05) were
observed between the groups. At day 14 p.i. extensive growth of blood vessels and
ulceration were seen in the infected cornea of siLuc-treated mice. siVEGF mixtreated mice showed less neovascularization near the limbal area (C).
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Figure 6. Decreased level of VEGF mRNA in the cornea that was infected and
treated with siVEGFmix with either local or systemic delivery.
Two corneas were collected at day 4 or 7 p.i. from mice that were infected with
5

1×10 PFU HSV-1 RE and were treated with siRNAs targeting VEGF-pathway
genes at day 1 and 3 p.i. by either local (10 µg, subconjunctival; S/C) or systemic
(40 µg, tail vein) administration and then VEGF mRNA level was measured by
RT-PCR (A) or quantitative real-time PCR (B).
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Figure 7. Reduced levels of VEGF protein in the cornea that was infected and
treated with siVEGFmix with either local or systemic delivery.
At day 7 p.i. 2 corneas/mouse were processed to measure the VEGF protein levels.
Levels of VEGF were estimated from supernatants of corneal lysates of mice
infected with HSV-1 and treated with siRNAs targeting VEGF-pathway genes by
an antibody capture ELISA as outlined in materials and methods. Results are
expressed as mean ± SD of four separate mice (2 corneas per mouse). *
Statistically significant differences in VEGF protein levels (p < 0.05) were
observed between the groups.
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Figure 8. Ocular delivery of FITC-labeled siRNA.
siLuc-FITC (10 µg for local injection and 40 µg for systemic injection) with
polymer or PBS control was delivered 24 h after the CpG ODN induction. 18 h
after siLuc-FITC injection, eyes were frozen and six-micron-thick sections were
cut. Local as well as systemic delivery of siRNAs with FITC fluorescences was
demonstrated in the limbal area by microscopic observation. The white arrows
indicate FITC fluorescences.
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Figure 9. Schematic structure of TargeTran.
TargeTran contains three functional domains: a cationic core, a steric polymer, and
a peptide ligand. The polymer electrically interacts with nucleic acids, and initiates
self-assembly into nanoparticles that deliver the siRNAs selectively to cells with
the receptor of the ligand.
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Part III
Application of Plasmid DNA Encoding IL-18
Diminishes Development of Herpetic Stromal
Keratitis by Antiangiogenic Effects
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Research described in this chapter is a slightly modified version of an article
published in 2005 in The Journal of Immunology by Bumseok Kim, Sujin Lee,
Susmit Suvas and Barry T. Rouse

Kim, B., S. Lee, S. Suvas, and B. T. Rouse. 2005. Application of plasmid DNA
encoding IL-18 diminishes development of Herpetic Stromal Keratitis by
antiangiogenic effects. J. Immunol. 175(1): 509-516. Copyright 2005. The American
Association of Immunologist, Inc.
In this chapter “we” and “our” refers to co-authors and me. My contributions in the
paper include (1) selection of the topic (2) data analysis and interpretation (3)
planning experiments (4) compiling and interpretation of the literature (5)
understanding how results fit with the literature (7) compilation of contributions
into one paper (8) providing structure to the paper (9) making graphs, figures and
tables (10) writing and editing.

ABSTRACT
Herpes simplex virus-1 (HSV-1) infection of the eye can cause a blinding
immunoinflammatory stromal keratitis (SK) lesion. Using the mouse model, we
have demonstrated that angiogenesis is an essential step in lesion pathogenesis
since its inhibition results in diminished severity. The molecules involved in
causing corneal angiogenesis are multiple and include the vascular endothelial
growth factor (VEGF) family of proteins. In this report we show that application
of plasmid DNA encoding IL-18 to the cornea of mice prior to HSV-1 ocular
infection resulted in reduced angiogenesis and diminished SK immuno89

inflammatory lesions. The antiangiogenic effects of IL-18 treatment appeared to be
mediated by inhibition of VEGF production in the cornea. We also showed that
IL-18 controlled VEGF expression in vitro and also decreased CpG
oligodeoxynucleotide (ODN) induced VEGF dependent neovascularization. In
addition the administration of IL-18 binding protein (IL-18 BP), an IL-18
antagonist, into the inflammatory eye resulted in elevated angiogenesis and
increased VEGF expression. Our results indicate that IL-18 is an important
endogenous negative regulator of HSV-induced angiogenesis resulting in reduced
SK lesion severity. Our results could mean that IL-18 administration may
represent a useful approach to manage unwanted angiogenesis.

INTRODUCTION
Herpes simplex virus (HSV) infection of the eye commonly results in a blinding T
cell mediated immunoinflammatory lesion (1), (2). One prominent early event in
the pathogenesis of stromal keratitis (SK) is neovascularization of the usually
avascular cornea. Indeed, inhibiting the angiogenic process may result in
diminished SK lesions (3). It has become apparent that angiogenesis is a complex
multi-step process that includes proliferation and migration of endothelial cells
from preexisting blood vessels in response to many angiogenic factors as well as
degradation of the extracellular matrix which facilitates neovessel ingress (4).
These multiple steps are likely subject to different control measures. For example,
it is believed that the local changed balance between angiogenic and angiostatic
molecules could switch an angiogenic phenotype (5). Some cytokines may
participate in regulating this angiogenic switch. For instance, some cytokines such
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as IL-8 (6), IL-6 (7), and IL-1 (8) stimulate angiogenesis, whereas others such as
IL-12 (9), platelet factor 4 (PF4) (10) and IFN-inducible protein-10 (IP-10) (11)
inhibit neovascularization. Recently, it became evident that IL-18, a cytokine that
shares several properties of IL-12, may induce tumor regression that involves
inhibition of angiogenesis by suppression of endothelial cell proliferation (12, 13)
and promotion of IFN-γ release (12). Recent studies in a vascular ischemic disease
model showed that in vivo application of plasmid DNA encoding murine IL-18
binding protein (IL-18BP, the endogenous inhibitor of IL-18) stimulated ischemiainduced angiogenesis indicating that IL-18 plays an antiangiogenic role in the
ischemic model. Furthermore, the addition of IL-18 to human umbilical vein
endothelial

cells

(HUVECs)

completely

abrogated

VEGF-induced

Akt

phosphorylation in endothelial cells (14). In addition, it was reported that IL-18
knockout mice have abnormal retinal vascular development because of overexpression of several angiogenesis-associated factors in the retina (15). By contrast,
IL-18 may induce endothelial cell migration and could act as an angiogenic factor
(16), although this observation remains unconfirmed. Most reports indicate that
IL-18 is on balance an antiangiogenic factor, but the precise mechanism by which
IL-18 exerts this effect remains unresolved. In the present study, we have
measured the effects of IL-18 on angiogenesis induced by HSV infection of the
mouse eye. Our results demonstrated that its antiangiogenic effects occurred via
inhibition of the expression of VEGF, a major factor in HSV induced ocular
angiogenesis. To our knowledge this demonstration of a direct effect of IL-18 on
VEGF expression in vitro has not previously been reported.
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MATERIALS AND METHODS
Reagents
Phosphorothioate ODNs were kindly provided by Dennis M. Klinman (Biologics
Evaluation and Research, FDA, U.S.A.). The sequences of stimulatory ODNs used
in this study were: 1466, TCAACGTTGA, and 1555, GCTAGACGTTAGCGT.
Subsequent studies were performed using an equimolar mixture of ODNs 1466
and 1555.

Mice
Female 4-to-5 week old BALB/c mice were purchased from Harlan SpragueDawley (Indianapolis, IN). To prevent bacterial infection, all mice received
treatment with sulfamethoxazole/trimethoprim (Biocraft, Elmond Park, NY) at the
rate of 5 ml/200 ml drinking water. All investigations followed guidelines of the
Committee on the Care of Laboratory Animals Resources, Commission of Life
Sciences, National Research Council. The animal facilities of the University of
Tennessee (Knoxville) are fully accredited by the American Association of
Laboratory Animal Care.

Virus and corneal HSV infection
HSV-1 strain RE (kindly provided by Dr. Robert Lausch, University of Alabama,
Mobile) was used in all procedures. Virus was grown in Vero cell monolayers
(American Type Culture Collection, Manassas,VA; Cat.no.CCL81), titrated, and
stored in aliquots at -80°C until used. Corneal infections of all mouse groups were
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conducted under deep anesthesia induced by Avertin. The mice were scarified
lightly on their corneas with a 32 gauge needle and infected with a 2 µl drop
containing 106 or 3× 105 plaque-forming units (PFU) of HSV-1 RE that was
applied to the eye and gently massaged with the eyelids.

Plasmid DNA preparation and administration
Plasmid DNA encoding murine IL-18 was kindly provided by Dr. Kenji Okuda
(Yokoyama City University School of Medicine, Japan) and pCDNA3.1-GFP was
used as control. The plasmid DNA used in this work was inserted into the
pCDNA3.1 expression vector (Invitrogen, San Diego, CA). The plasmid DNA was
purified by a polyethylene glycol precipitation method. The quality of DNA was
measured by electrophoresis on 1% agarose gel. Protein expression of the different
plasmids was determined by dot blot after in vitro transfection of Chinese hamster
ovary (CHO) cells.
Plasmid DNA (100 µg) was suspended in 4 µl sterile phosphate-buffered
saline (PBS). Corneas were scarified using a 32 gauge needle in a criss-cross
pattern, and the plasmid was administered intraocularly on 4 and 2 days before
virus infection.

Cell culture
BALB/c mouse brain microvascular endothelial (MBE) cells were kindly provided
by Dr. Auerbach (University of Wisconsin). MBE cells were grown in DMEM
supplemented with 10% FCS. They were maintained in culture at the University of
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Tennessee with no signs of cell senescence after they were received from the
University of Wisconsin.

Cell proliferation assay (DNA synthesis assay)
Recombinant mouse IL-18 (Medical & Biological Laboratories Co., Woburn, MA)
or OVA (Sigma Co., St. Louis, MO) was tested for the ability to stimulate
proliferation of mouse endothelial cells (17). Accordingly, MBE cells (1,000
cells/well) were seeded onto 96 well tissue culture plates and incubated in 10%
DMEM for 12 h. To maximize activation MBE cells were then stimulated with
recombinant bFGF (10 ng/ml, R&D system) for 12 h in 0.4% DMEM. Activated
MBE cells were treated with different recombinant proteins (IL-18 or OVA) in
0.4% DMEM at various doses (0.1, 1, 10, 100 ng/ml). After 16 hours cells were
pulse labeled with 3H-thymidine (1 µCi/mL) for 6 h. The level of thymidine
incorporation was then measured using a beta scintillation counter (Inotech,
Lancing, Mich.).

Intracellular detection of VEGF
For intracellular detection of VEGF, MBE cells (5,000 cells/well) were seeded
onto 24 well tissue culture plates and incubated in 10% DMEM for 12 h. MBE
cells were then stimulated with bFGF (10 ng/ml) for 12 h in 0.4% DMEM.
Stimulated MBE cells were then treated with recombinant IL-18 or OVA as a
control in 0.4% DMEM using various concentrations (0.01, 0.1, 1, 10, 100 ng/ml).
After 24 h of incubation adherent cells were dispersed in trypsin-EDTA and
resuspended in FACS solution. For intracellular staining for VEGF the cells were
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then fixed in paraformaldehyde and stained for VEGF by using biotinylated ratanti-mVEGF164 antibody (0.2 µg/well, R&D system) followed by streptavidin-PE
(0.2 µg/well, BD Pharmingen). Positive cells and mean fluorescence were
measured by flow cytometry using a FACScan (BD Biosciences, Mountain View,
CA). The data were analyzed using the CellQuest 3.1 software (BD Biosciences).

Clinical observations
The eyes were examined on different days after infection for the development of
clinical lesions by slit-lamp biomicroscopy (Kawa Co, Nagoya, Japan), and the
clinical severity of keratitis of individually scored mice was recorded. The scoring
system was as follows: 0, normal cornea; +1, mild corneal haze; +2, moderate
corneal opacity or scarring; +3, severe corneal opacity but iris visible; +4, opaque
cornea and corneal ulcer; +5, corneal rupture and necrotizing stromal keratitis. The
severity of angiogenesis was recorded as described previously (3). In reference to
the angiogenic scoring system, the method relied on quantifying the degree of
neovessel formation based on three primary parameters: 1) the circumferential
extent of neovessels (as the angiogenic response is not uniformly circumferential in
all cases); 2) the centripetal growth of the longest vessels in each quadrant of the
circle; and 3) the longest neovessel in each quadrant was identified and graded
between 0 (no neovessel) and 4 (neovessel in the corneal center) in increments of
~0.4 mm (radius of the cornea is ~1.5 mm). According to this system, a grade of 4
for a given quadrant of the circle represents a centripetal growth of 1.5 mm toward
the corneal center. The score of the four quadrants of the eye were then summed to
derive the neovessel index (range, 0 to 16) for each eye at a given time point.
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RNA extraction and RT PCR
At 24 h following IL-18 treatment the cells were harvested and RNA was extracted
by using an RNeasy protect mini kit (Qiagen, Valencia, CA). For ocular infections,
2 corneas/time point were excised and transferred to RNAlaterTM. Briefly, cells
were lysed in RLT buffer (Qiagen, catalog no. 79216) and RNA was purified
according to manufacturer’s instructions. An RNase-free Dnase set (Qiagen) was
used to remove any contaminating genomic DNA. Total cellular RNA (10 µg/ml)
was reversed-transcribed using oligo (dT) primers and reverse transcriptase
(Promega, Madison, WI) according to protocols described previously (18). The
cDNA was made by reverse-transcription at 42°C for 90 min. The primer
sequences for mVEGF RT-PCR were: 5’-GCGGGCTGCCTCGCAGTC-3’ (sense)
and 5’-TCACCGCCTTGGCTTGTCAC-3’ (antisense). RT-PCR products were
644 bp for mVEGF164 and 512 bp for mVEGF120. The primer sequences for
mIL-18 RT-PCR were: 5’-ATGGCTGCCATGTCAGAAG-3’ (sense) and 5’TAACTTTGATGTAAGTTAGTGAGAG-3’ (antisense). The amplification profile
was 94°C for 1 min, 65°C for 1 min, and 72°C for 15 min for 30 cycles. The PCR
products were separated by 1% agarose gel electrophoresis.

VEGF quantification of culture supernatants or corneal lysates by ELISA
The culture supernatants from recombinant protein (IL-18 or OVA) treated MBE
cells, lysates from IL-18 DNA or IL-18 BP (2 µg/cornea, R&D system) treated
CpG ODNs implanted, as well as HSV-1 infected cornea were used for the
measurement of VEGF by a standard sandwich enzyme-linked immunosorbent
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assay (ELISA) protocol. For preparation of corneal lysates, two corneas/time point
(n = 4) were collected and minced with liquid nitrogen. Minced pieces were
collected in 1 ml of DMEM without FCS and homogenized using an ultra sonicater
(Heat systems-Ultrasonics, NY, U.S.A.). The lysates were then clarified by
centrifugation at 12,000 rpm for 5 min at 4°C. The supernatant was collected and
stored at –80°C till further use. The ELISA plate was coated with anti-mouse
VEGF capture antibody (100 µl/well of the capture antibody at 0.4 µg/ml, R&D
system) and incubated at 4°C overnight. The plate was washed with 0.05%
tween20/PBS and blocked with 3% BSA for 2 h at 37°C. After washing, serially
diluted corneal lysates were added to the plate and incubated at 4°C overnight. The
plate was washed and then incubated with anti-VEGF biotinylated detection Ab
(50 ng/ml, R&D system) for 2 h. Finally, peroxidase-conjugated streptavidin
(Jackson ImmunoResearch Laboratory, PA, U.S.A.) was added. The color reaction
was developed using ABTS (Sigma-Aldrich, St. Louis, MO) and measured with an
ELISA reader (Spectramax 340; Molecular Devices, Sunnyvale, CA) at 405 nm.
Quantification was performed with Spectramax ELISA reader software version 1.2.

Intrastromal corneal injection and micropocket assay
A nick in the epithelium and anterior stroma of a BABL/c mouse cornea was made
in the mid periphery with a 32 gauge needle (Becton Dickinson, Franklin Lakes,
NJ) under direct microscopic observation. A blunt 32 gauge needle with a 30o
bevel was introduced into the corneal stroma and advanced to the corneal center. 2
µl (1 µg of IL-18 or GFP DNA) of plasmid solution was injected under pressure
into the stroma to separate corneal lamellae and disperse the plasmid.
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In vivo angiogenic activity was assayed in the avascular cornea of mouse
eyes as previously described (19). Briefly, mice were pretreated with plasmid
DNA encoding IL-18 DNA and control GFP DNA intrastromally 1 day before
implantation of pellets. Pellets for insertion into the cornea were made by
combining known amounts of CpG ODNs, sucralfate (10 mg, Bulch Meditec) and
hydron polymer in ethanol (120 mg/1 ml ethanol, Interferon Sciences), and
applying the mixture to a 15×15 mm2 piece of synthetic mesh (Tekto). The
mixture was allowed to air dry and fibers of the mesh were pulled apart, yielding
pellets containing 1 µg of CpG ODNs. Pellets containing CpG ODNs were
implanted into an intracorneal pocket (1 mm from the limbus). The eyes were then
evaluated for corneal neovascularization. The extent of the neovessel ingrowth was
recorded by direct measurement using calipers (Symbol of Quality, biomedical
research instruments, Rockville, Maryland) under stereomicroscopy (Leica
Microsytems, Wetzlar, Germany). The length of the neovessels originating from
the limbal vessel ring toward the center of the cornea and the width of the
neovessels presented in clock hours were measured. Each clock hour is equal to
30˚ at the circumference. The angiogenic area was calculated according to the
formula for an ellipse. A = [(clock hours) × 0.4 × (vessel length in mm) × π] / 2.

Subconjunctival injection of IL-18 BP
Mice were treated with recombinant IL-18 BP and control OVA protein (2
µg/10µl PBS per eye) subconjunctivally on day 0 and 2 after implantation of CpG
ODNs pellets containing 500 ng or after infection with HSV-1 RE (3× 105 PFU).

98

The eyes were then evaluated for corneal neovascularization or herpetic SK lesion
severity.

Statistical analysis
Significant differences between groups were evaluated by using the Student’s t test.
P < 0.05 was regarded as a significant difference between two groups.

RESULTS
Application of Plasmid DNA encoding IL-18 decreases the severity and
incidence of SK
An initial experiment was performed to determine if the expression of IL-18 in
corneas prior to HSV infection had any effect on the severity of SK lesions. To
express IL-18 in the cornea, mice were treated with 100 µg of plasmid DNA
encoding IL-18 on their scarified corneas four and two days before virus infection,
with control animals receiving the plasmid DNA encoding GFP. Subsequently, the
corneas of mice were infected with 106 plaque-forming units (PFU) of HSV-1 RE.
As shown in Fig. 1 (A and B), IL-18 pre-exposure resulted in decreased average
severity and percentage of animals with clinical lesions compared to control DNA
treated mice. A comparison of average severity scores on days 12, 15, and 21 p.i.
was all significantly less in the IL-18 treated than the control group (p < 0.05).
Recently IL-18 was claimed to exert antiviral effects (20) against HSV-1 infection
(21) due to augmentation of IFN-γ. This mechanism, however, seemed not to
explain our findings since comparisons of viral yields and duration of detectable
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virus in IL-18 pretreated and control cornea showed no statistically significant
differences (Data not shown).

Suppression of HSV-induced angiogenesis
One essential step in the pathogenesis of SK is angiogenesis mediated by several
angiogenesis factors. Thus, one explanation considered to explain the inhibitory
effects of IL-18 on SK was anti-angiogenesis. To record such an effect, levels of
neovascularization were measured in the corneas by biomicroscopy in groups of
mice either pretreated with IL-18 DNA or control plasmid prior to HSV infection.
The results shown in Fig. 1C indicate that levels of angiogenesis were significantly
less at most time points tested in the IL-18 DNA compared to control plasmid
treated animals.

Suppressed expression of VEGF in the HSV-1 infected cornea by IL-18
Previous reports on HSV-1 induced angiogenesis have identified VEGF as a
molecule that is highly expressed in the infected eye and clearly involved in
angiogenesis (19). To evaluate whether treatment of IL-18 DNA inhibits HSV-1
induced angiogenesis by decreased expression of VEGF gene in the cornea we
measured VEGF mRNA and protein levels in IL-18 pretreated and HSV-1 infected
corneas at day 2 and 4 after infection. As shown in Fig. 2A and B, VEGF mRNA
and protein levels were lower in those that received IL-18 DNA compared to
controls given control DNA at day 4 (p < 0.05). This result suggests that the target
gene of IL-18 with angiostatic function is the VEGF molecule in the SK cornea.
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Inhibition of CpG-induced corneal neovascularization by IL-18
A previous study demonstrated that CpG containing ODNs encapsulated in hydron
pellets induce VEGF mediated angiogenesis when inserted into corneal
micropockets (22, 23). Hence, attempts were made to determine if VEGF
expression and function were affected by IL-18. In the first approach, the effects
of IL-18 plasmid expression in the eye were tested for the ability to affect the
extent of angiogenesis caused by CpG ODNs using a corneal micropocket assay.
In this experiment pretreatment of IL-18 DNA markedly inhibited (approximately
60% inhibition) the extent of CpG-induced angiogenesis compared to control
DNA treated animals (Fig. 3A and B).
To evaluate whether treatment of IL-18 diminished the production of
VEGF protein in the CpG stimulated cornea, VEGF protein levels were compared
in IL-18 and control DNA treated corneas at day 4 and 7 after CpG implantation.
As shown in Fig. 3C, VEGF protein levels were significantly lower (p < 0.05) in
the IL-18 DNA treated group, but significant differences from controls were only
evident in the day 7 samples. These results show that administration of IL-18
inhibited neovascularization by suppression of VEGF production in the CpG
induced inflammatory cornea.

Suppression of VEGF expression and production in vitro by IL-18
Additional experiments regarding the anti-angiogenic effects of IL-18 were
performed in vitro using an endothelial cell line derived from mouse brain
endothelial (MBE) cell that produces VEGF endogenously. To investigate whether
IL-18 inhibits VEGF expression and production in vitro, different concentrations
101

of recombinant IL-18 were incubated with MBE cells pre-stimulated by 10 ng/ml
FGF-2 for 12 h as described in materials and methods. At 24 h after IL-18
treatment cell supernatants or cells were collected and VEGF expression and
production were measured by RT-PCR, ELISA, or intracellular staining,
respectively. As shown in Fig. 4A, expression of both the 120 and 164 isoforms of
VEGF was reduced by recombinant IL-18 in a dose dependent manner.
Furthermore, VEGF production in cell lines was significantly reduced in IL-18
treated cell lines compared to control OVA protein treated cell lines (Fig. 4B, P <
0.05 or P < 0.01). Also, the intensity of intracellular VEGF fluorescence was
markedly decreased by the addition of IL-18 (Fig. 4C and D). This downregulation
of VEGF production and expression occurred in a dose-dependent manner and was
clearly evident when compared with cells incubated with OVA. In addition, VEGF
expression was not decreased by incubation with different concentrations of
recombinant IL-12, a cytokine that shares several properties of IL-18 (data not
shown). To exclude the possibility of non-specific gene suppression by IL-18, we
also measured the expression of bFGF, but no suppression of this gene was
detected (data not shown). Furthermore, no apoptosis of cells following IL-18
treatment was observed by the Annexin-V staining method (data not shown).

Inhibitory effects of IL-18 on endothelial cell proliferation
Angiogenesis involves growth of endothelial cells (proliferation and migration)
and other vascular components from existing blood vessels (24). The effect of IL18 on endothelial cell proliferation was tested using the endothelial cell line MBE.
In these experiments cells recently stimulated by 10 ng/ml FGF-2 were washed
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and exposed to different concentrations of IL-18. After 24 h incubation the effect
on proliferation was measured by a short term pulse with 3H-thymidine. At the
concentration of 100 and 10 ng/ml, IL-18 inhibited significantly endothelial cell
proliferation by 53 and 30% respectively (P < 0.05) (Fig. 5). IL-18 was shown to
inhibit endothelial cell proliferation in a dose-dependent way. These data also
suggest that inhibition of angiogenesis by IL-18 is mediated by the suppression of
endothelial cell proliferation.

Upregulation of VEGF by IL-18 BP in the inflammatory cornea
A previous study showed that several angiogenesis-associated factors including
VEGF were overexpressed in the retinas of IL-18 KO mice and indicated that the
endogenous IL-18 regulates VEGF expression in the retina (15). Therefore, we
tested whether endogenous IL-18 may also regulate VEGF expression in the
cornea. First we measured endogenous IL-18 mRNA expression in naïve and virus
infected cornea. As shown in Fig. 6A, IL-18 was present in normal corneal
extracts, and the IL-18 mRNA expression was slightly increased in the SK cornea.
It is known that IL-18 BP functions as an IL-18 antagonist by binding to IL-18 and
blocking its biological activity (14). To investigate the effect of endogenous IL-18
on corneal angiogenesis, IL-18 BP was used to block endogenous IL-18 in both
virus infected and CpG implanted eye. The corneas of mice were infected with 3 ×
105 PFU of HSV-1 RE followed by treatment with 2 µg of recombinant IL-18 BP
in the subconjunctival area at day 0 and 2 after virus infection. As shown in Fig. 6
(B and C), IL-18 BP application resulted in more severe SK lesions and increased
angiogenesis compared to control OVA treated mice. A comparison of average
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severity scores after day 4 p.i. or angiogenesis scores spanning all time points were
all significantly higher in the IL-18 BP treated group than the control group (* p <
0.05, ** p < 0.01). In addition, corneas were implanted with 500 ng of CpG ODNs
pellets and then treated with 2 µg of recombinant IL-18 BP by subconjunctival
injection at day 0 and 2 after pellet implantation. The IL-18 BP treatment was
shown to significantly increase the CpG-induced angiogenesis (Fig. 6D). We
further investigated the expression levels of VEGF mRNA and protein in the CpG
stimulated and IL-18 BP treated cornea. VEGF mRNA and protein were
upregulated in the IL-18 BP treated corneas compared to those of the OVA treated
mice (Fig. 6E and F). We could exclude the possibility that IL-18 BP itself is an
angiogenic factor, since injection of IL-18 BP into the normal cornea failed to
cause significant levels of angiogenesis (data not shown). Taken together our
results indicate that endogenous IL-18 may control the angiogenesis induced by
inflammation.

DISCUSSION
In the present study, we show that the administration of plasmid DNA encoding
IL-18 to the cornea of mice prior to HSV ocular infection results in diminished
immunoinflammatory lesions. The diminished SK lesion severity by IL-18
treatment was caused by the inhibitory effect on corneal neovascularization, an
essential step in the pathogenesis of herpetic SK. One major factor induced by
HSV ocular infection that is angiogenic is VEGF (19). By both in vitro and in vivo
approaches we show that IL-18 resulted in a diminished VEGF response, although
the actual mechanism by which this was mediated was not defined. Application of
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IL-18 controlled VEGF expression in endothelial cells and also decreased HSV or
CpG induced VEGF dependent neovascularization. In addition the administration
of IL-18 binding protein (IL-18 BP), an IL-18 antagonist, into the inflammatory
eye resulted in elevated angiogenesis and increased VEGF expression. We
interpret these observations to indicate that IL-18 is an important endogenous
negative regulator of HSV-induced angiogenesis resulting in reduced SK lesion
severity.
The activity of endogenous IL-18 can be regulated by IL-18 BP, a secreted
protein possessing a high-affinity binding and ability to neutralize IL-18 (25).
Recent several studies associated with IL-18/IL-18 BP signaling have shown that
IL-18 BP efficiently inhibits the IL-18 activity in many inflammatory disease
models (14, 26).

Since endogenous IL-18 was present in normal as well as

infected corneas, IL-18 BP was applied to the infected or CpG implanted eye to
demonstrate the antiangiogenic role of endogenous IL-18 in our SK model.
Blocking of endogenous IL-18 by administration of IL-18 BP increased VEGF
expression and angiogenesis in the virus infected as well as CpG implanted cornea,
further demonstrating that IL-18 is antiangiogenic. Since VEGF expression in the
inflammatory cornea was localized to inflammatory cells including neutrophils and
macrophages, it seems that endogenous IL-18 may control VEGF expression in
inflammatory cells as well as proliferating endothelial cells. In addition, the fact
that there is no angiogenesis in the normal cornea treated with IL-18 BP supports
the idea that endogenous IL-18 regulates VEGF expression in the inflammatory
environment.
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IL-18 was first identified as an IFN-γ inducing factor and proinflammatory
cytokine (27), but it may mediate several additional biological functions. For
example, IL-18 can induce TNF-α or Fas-ligand related cell cytotoxicity (28) and
mediate inflammatory tissue damage (29). In addition, IL-18 can skew naïve T
cells towards a Th-1 type phenotype by decreased synthesis of IL-10 and increased
production of IFN-γ (30). IL-18 is a member of the IL-1 family, with structural
similarity and some common biological activities (31). However, IL-18 most
closely resembles IL-12, as both are potent inducers of IFN-γ (27). Although IL-12
has also been reported to be a potent anti-angiogenic factor through effects on
IFN-γ signaling (32), the function of IL-18 on angiogenesis has not been clearly
defined. Previously we showed that the anti-angiogenic effects of IL-12 on HSV
induced angiogenesis was mediated by IFN-γ induced antiangiogenic chemokines
such as IP-10 and MIG (9). However the antiangiogenic effects of IL-18 appeared
to differ from IL-12. Thus IL-18, unlike IL-12, could inhibit endothelial cell
proliferation and had direct inhibitory effects on VEGF production in vitro and in
vivo. Furthermore, IL-18 treatment had no effect on IFN-γ induction in endothelial
cells (data not shown), indicating that the antiangiogenic effects of IL-18 does not
appear to involve signaling through IFN-γ as occur with IL-12.
The over-expression of several potent angiogenic factors including VEGF,
bFGF, and PDGF-A genes in the retina (15), or the upregulation of VEGF mRNA
in the hindlimb after ischemic injury, has been previously reported in IL-18 KO
mice (14). Our data again support the idea that IL-18 has angiostatic function and
shows its function in the SK model. Although it was reported that IL-18 induces
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endothelial cell migration and tube formation (16), it could be that endothelial cell
proliferation induced by potent angiogenic factors may be more important than
endothelial cell migration for the process of angiogenesis. This issue is under
further investigation.
Taken together our results indicate that IL-18 may act as an endogenous
negative regulator of angiogenesis caused by inflammatory stimuli. In fact the eye
has low levels of IL-18 which if inhibited by administration of IL-18 BP,
subsequent levels of HSV induced angiogenesis and SK become significantly
increased. Manipulating the function of IL-18 could represent a useful approach to
control unwanted angiogenesis.
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Figure 1. Inhibition of SK lesion severity (A), incidence (B), and HSV-induced
angiogenesis (C) by IL-18 DNA administration.
Groups of animals (n=6) were treated intraocularly at 2 and 4 days before virus
infection with 100 µg IL-18 DNA (ο) or control GFP DNA (•). Two days after the
second treatment, animals were infected with 106 PFU of HSV-1 RE on their
scarified corneas and subsequently scored for lesion severity by slit-lamp
biomicroscopy. The data are compiled from three independent experiments.
Statistically significant differences in SK (A) and angiogenic (B) score were
observed between the groups (* p < 0.05, ** p < 0.01).
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Figure 2. Reduced levels of VEGF mRNA and protein in the HSV-1 infected
cornea by IL-18 treatment.
At day 2 and 4 p.i. 2 corneas/mouse that were pretreated with IL-18 and infected
6

with 1×10 pfu HSV-1 RE were processed to measure the VEGF mRNA or protein
levels. VEGF mRNA levels were measured by RT-PCR (A). Levels of VEGF
protein were estimated from supernatants of corneal lysates of mice by an antibody
capture ELISA as outlined in materials and methods. Results are expressed as
mean ± SD of four separate mice (2 corneas per mouse). * Statistically significant
differences in VEGF protein levels (p < 0.05) were observed between the groups at
day 4 after viral ocular infection (B).
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Figure 3. Inhibition of the CpG ODN-induced angiogenesis via diminished
VEGF production by IL-18 pretreatment.
24 h before implantation with CpG ODN (1 µg) into the micropocket of mouse
corneas, mice were given 1 µg per eye of IL-18 or GFP control plasmid by
intrastromal injection. The angiogenesis area (A) was measured on day 4 and 7
after the CpG pellets implantation (four mice per group). Images were taken by
stereomicroscopic imaging system at day 4 after CpG pellets implantation
(original magnification, x40) (B). At day 4 and 7 after CpG pellet implantation 2
corneas/mouse were processed to measure the VEGF protein levels (C). Levels of
VEGF were estimated from supernatants of corneal lysates of mice pretreated with
IL-18 and implanted with CpG ODN (1 µg) by an antibody capture ELISA as
described in materials and methods. Results are expressed as the mean ± SD of
four separate mice (2 corneas per mouse). Statistically significant differences in
angiogenic areas (A) and VEGF protein levels (C) (* p < 0.05) were observed
between the groups.
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Figure 4. Suppression of VEGF expression and production by IL-18 incubation
in vitro.
MBE cells that normally produce VEGF endogenously were prestimulated by 10
ng/ml FGF-2 for 12 h and then incubated with different concentrations of
recombinant IL-18 for 24 h. Cells were collected and VEGF mRNA levels were
measured by RT-PCR (A). Cell supernatants were used to measure VEGF protein
levels by ELISA as described in materials and methods. Statistically significant
differences in VEGF protein levels were observed between the groups (* p < 0.05,
** p < 0.01) (B). MBE cells incubated with IL-18 for 24 h were collected and
resuspended in FACS solution (PBS-3% FCS containing 0.1% Sodium Azide).
The cells were then fixed in paraformaldehyde and stained for VEGF by using
biotinylated rat-anti-mVEGF164 antibody followed by streptavidin-PE. Positive
cells and mean fluorescence were measured by flow cytometry (C and D). VEGF
expression was not decreased by incubation with different concentrations of
recombinant IL-12, a cytokine that shares several properties of IL-18 (data not
shown).
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Figure 5. Inhibition of endothelial cell proliferation by IL-18.
MBE cells pre-stimulated with FGF-2 (10 ng/ml) were incubated with various
concentrations (100, 10, 1, 0.1 ng/ml) of recombinant IL-18 or OVA as described
in Material and Methods. After 18 hours cells were pulse labeled with 3Hthymidine (1 µCi/mL) for 6 h. The amount of radioactivity incorporated into the
trichloroacetic acid–precipitable material was measured. * Statistically significant
differences in radioactive levels (p < 0.05) were observed between the IL-18 and
OVA treated groups.
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Figure 6. Increased angiogenesis and upregulation of VEGF by IL-18 BP.
Mice were infected as described in the material and mathods. At different time
points p.i. the corneas (n = 4) were isolated and stored at -80°C. Total RNA was
extracted from the samples and reverse transcribed into cDNA. PCR was
performed to detect the IL-18 in both uninfected and HSV-infected corneas (A).
Groups of animals (n = 4) were treated subconjunctivally at 0 and 2 days after
virus infection (3 × 105 PFU) with recombinant IL-18 BP(•) or control OVA (ο) (2
µg/10 µl) and subsequently scored for lesion severity by slit-lamp biomicroscopy.
Statistically significant differences in SK (B) and angiogenic (C) score were
observed between the groups (* p < 0.05, ** p < 0.01). Day 0 and 2 after
implantation with CpG ODN (500 ng) into the cornea, mice were given 2 µg per
eye of IL-18 BP or OVA protein as a control group by subconjunctival injection.
The angiogenic area (D) was measured on day 4 and 7 after the CpG pellet
implantation (four mice per group).
At days 4 and 7 after CpG pellets implantation IL-18 BP or OVA treated
corneas were processed to measure the VEGF mRNA expression. VEGF mRNA
levels were measured by RT-PCR (E). At day 4 after CpG pellet implantation IL18 BP or OVA treated corneas (4 corneas per group) were processed to measure
the VEGF protein level (F). Levels of VEGF were estimated from supernatants of
corneal lysates of mice treated with IL-18 BP by an antibody capture ELISA as
described in materials and methods.
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Part IV
VEGF Receptor 2 Based DNA Immunization
Prevents Herpetic Stromal Keratitis by
Antiangiogenic Effects
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In this chapter “we” and “our” refers to co-authors and me. My contributions in the
paper include (1) selection of the topic (2) data analysis and interpretation (3)
planning experiments (4) compiling and interpretation of the literature (5)
understanding how results fit with the literature (7) compilation of contributions
into one paper (8) providing structure to the paper (9) making graphs, figures and
tables (10) writing and editing.

ABSTRACT
Stromal keratitis (SK) is an immunoinflammatory eye lesion caused by herpes
simplex virus-1 (HSV-1) infection. It has been previously shown that abnormal
angiogenesis in normally avascular cornea contributes the pathogenesis of SK
lesions and vascular endothelial growth factor (VEGF) family of proteins is
responsible for pathological corneal neovascularization. In this report, we targeted
the proliferating vascular endothelial cells expressing VEGF receptor 2 (VEGFR-2,
FLK-1) in the SK cornea by immunization with attenuated Salmonella
typhimurium harboring murine FLK-1. FLK-1 based DNA vaccination resulted in
diminished angiogenesis caused by HSV-1 infection or by recombinant VEGF
corneal implantation. Strong CTL against endothelial cells expressing FLK-1 was
evident in the FLK-1 immunized group, indicating that FLK-1 specific CD8+ T
cells are responsible for the antiangiogenic effects. In addition in vivo CD8+ T cell
depletion resulted in the abrogation of the antiangiogenic immune response. Our
results indicate that FLK-1 based DNA vaccination efficiently induces a T cell
mediated immune response against activated endothelial cells overexpressing
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FLK-1 and this approach may represent a useful therapeutic strategy for SK
angiogenesis.

INTRODUCTION
Virus infections contribute to the onset of several inflammatory autoimmune
diseases (1-5). One autoimmune disease involved in this category is herpetic
stromal keratitis (SK), a corneal inflammatory lesion following herpes simplex
virus-1 (HSV-1) infection (6-8). In the mouse model, lesions of SK appear to be
mediated by autoreactive CD4+ T cells (9, 10). In addition, several inflammatory
cells including neutrophils (11) and macrophages (12-14) are infiltrated to the
immune privileged cornea. Since one of the early events in the pathogenesis of SK
is abnormal angiogenesis of the usually avascular cornea, it has been demonstrated
that infiltrated inflammatory cells producing various angiogenic factors are the
primary contributors to the uncontrolled process of angiogenesis after HSV
infection (15). These leaky new blood vessels in the stromal layer of cornea may
become a route for supply of inflammatory cells and CD4+ T cells, and
subsequently cause blindness. Indeed, inhibition of neovascularization by
antiangiogenic approaches could result in diminished SK lesions (16). Therefore,
several strategies to inhibit unwanted angiogenesis have been proposed for SK
lesion therapy (16-18).
It has recently been shown that multiple angiogenic molecules were
responsible for the HSV-induced angiogenesis (15, 19-21). Extensive studies in
SK, as well as tumor models, have demonstrated that vascular endothelial growth
factor (VEGF), one of the potent angiogenic factors, significantly contributes the
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pathological process of angiogenesis (15, 22, 23). Previous SK studies have shown
that HSV infection resulted in the induction of VEGF expression by CpGcontaining motifs of HSV DNA (24) as well as infiltrated inflammatory cells (15).
Additionally, virus infection stimulates release of various cytokines including IL-1
(21, 25) and IL-6 (20), and subsequently they induce VEGF production.
Accordingly, neutralization of VEGF with antibody (16), knock-down of VEGF
family genes with siRNAs targeting VEGF, VEGF receptor 1, and 2 (VEGFR-1
and -2) (17), or application of DNA encoding antiangiogenic genes (26)
diminished HSV-induced angiogenesis and SK lesions.
The role of VEGF in the process and regulation of angiogenesis has been
intensely investigated (27). It has been known that two receptor tyrosine kinases,
VEGFR-1 and 2 are related to the biological effects of VEGF (27). Although both
receptors are involved in angiogenesis, the VEGFR-2 signaling pathway is used
more for the studying of pathological angiogenesis since VEGFR-2 is highly
overexpressed in the activated endothelial cells and its signaling induces
proliferation and migration of endothelial cells (28). Therefore, several
antiangiogenic or immunotherapeutic approaches targeting endothelial cells
expressing VEGFR-2 have been used to inhibit pathological angiogenesis and
tumor growth, including immunization with VEGFR-2 protein (29) or mRNAloaded dendritic cells (30), with paraformaldehyde-fixed endothelial cells (31), or
disruption of VEGFR genes by various methods (32). These approaches indicate
that VEGFR-2 is highly implicated as a therapeutic target for inhibition of
unwanted angiogenesis. In the present study, we have immunized the mice with an
attenuated Salmonella typhimurium harboring FLK-1 cDNA to induce FLK-1
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specific immune response. Here we show that our immunization stimulates a
potent antiangiogenic response and efficiently reduces SK lesions through the
inhibition of HSV-induced ocular angiogenesis.

MATERIALS AND METHODS
Bacterial strains
Attenuated S. typhimurium Aro/A (strain SL7207) transformed with pcDNA3.1FLK-1 or -GFP was kindly provided by R.A. Reisfeld (Scripps Research Institute,
La Jolla, California, USA). The construction of expression vector encoding murine
FLK-1 was described previously (28). Protein expression of the different plasmids
was determined by immunohistochemical staining after in vitro transfection of
Cos-7 cells.

Mice
Female 5-to-6 week old BALB/c and C57BL/6J mice were purchased from Harlan
Sprague-Dawley (Indianapolis, IN). To prevent bacterial infection, all mice
received treatment with sulfamethoxazole/trimethoprim (Biocraft, Elmond Park,
NY) at the rate of 5 ml/200 ml drinking water after virus infection. All
investigations followed the guidelines of the Committee on the Care of Laboratory
Animals Resources, Commission of Life Sciences, National Research Council.
The animal facilities of the University of Tennessee (Knoxville) are fully
accredited by the American Association of Laboratory Animal Care.
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Oral immunization and corneal HSV infection
Mice were immunized by oral gavage 3 times at 2-wk intervals with 100 µl
sodium bicarbonate (NaHCO3) buffer containing 1 × 108 S. typhimurium
transformed with pcDNA3.1-FLK-1 or -GFP as a control. Corneas of mice were
infected 1 wk after final immunization. HSV-1 strain RE (kindly provided by Dr.
Robert Lausch, University of Alabama, Mobile) was used in all procedures. Virus
was grown in Vero cell monolayers (American Type Culture Collection,
Manassas,VA; Cat.no.CCL81), titrated, and stored in aliquots at -80°C until used.
Corneal infections of all mouse groups were conducted under deep anesthesia
induced by Avertin. The mice were scarified lightly on their corneas with a 32
gauge needle and infected with a 2 µl drop containing 5 × 105 plaque-forming
units (PFU) of HSV-1 that was applied to the eye and gently massaged with the
eyelids.

Clinical observations
The eyes were examined on different days after infection for the development of
clinical lesions by slit-lamp biomicroscopy (Kawa Co, Nagoya, Japan), and the
clinical severity of keratitis of individually scored mice was recorded. The scoring
system was as follows: 0, normal cornea; +1, mild corneal haze; +2, moderate
corneal opacity or scarring; +3, severe corneal opacity but iris visible; +4, opaque
cornea and corneal ulcer; +5, corneal rupture and necrotizing stromal keratitis. The
severity of angiogenesis was recorded as described previously (16). In reference to
the angiogenic scoring system, the method relied on quantifying the degree of
neovessel formation based on three primary parameters: 1) the circumferential
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extent of neovessels (as the angiogenic response is not uniformly circumferential in
all cases); 2) the centripetal growth of the longest vessels in each quadrant of the
circle; and 3) the longest neovessel in each quadrant was identified and graded
between 0 (no neovessel) and 4 (neovessel in the corneal center) in increments of
~0.4 mm (radius of the cornea is ~1.5 mm). According to this system, a grade of 4
for a given quadrant of the circle represents a centripetal growth of 1.5 mm toward
the corneal center. The score of the four quadrants of the eye were then summed to
derive the neovessel index (range, 0 to 16) for each eye at a given time point.

Corneal micropocket assay
In vivo angiogenic activity was assayed in the avascular cornea of mouse eyes as
previously described (16). Briefly, corneas of mice immunized with S.
typhimurium transformed with pcDNA3.1-FLK-1 or -GFP as a control were
implanted pellete containing 200 ng recombinant VEGF protein (R&D system).
Pellets for insertion into the cornea were made by combining known amounts of
VEGF protein, sucralfate (10 mg, Bulch Meditec) and hydron polymer in ethanol
(120 mg/ml ethanol, Interferon Sciences), and applying the mixture to a 15 × 15
mm2 piece of synthetic mesh (Tekto). The mixture was allowed to air dry and
fibers of the mesh were pulled apart, yielding pellets containing 200 ng of VEGF.
Pellets containing VEGF were implanted into an intracorneal pocket (1 mm from
the limbus). The eyes were then evaluated for corneal neovascularization. The
extent of the neovessel ingrowth was recorded by direct measurement using
calipers (Symbol of Quality, biomedical research instruments, Rockville,
Maryland) under stereomicroscopy (Leica Microsytems, Wetzlar, Germany). The
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length of the neovessels originating from the limbal vessel ring toward the center
of the cornea and the width of the neovessels presented in clock hours were
measured. Each clock hour is equal to 30˚ at the circumference. The angiogenic
area was calculated according to the formula for an ellipse. A = [(clock hours) ×
0.4 × (vessel length in mm) × π] / 2.

CTL assay
CTL activity was assessed by a standard 4-h
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Cr release assay against labeled

target cells as previously described (28). One week after final immunization,
splenocytes were collected from mice immunized with FLK-1 or GFP DNA.
Splenocytes were cocultured with irradiated (3000 rad) and mitomycin incubated
HEV (endothelial cell lines expressing VEGFR-2), CT-26 (murine colon
carcinoma cells), YAC cell lines. Five days later, the activated T cells were
harvested and tested for cytotoxicity.

Depletion of CD8+ T cells
We depleted CD8+ T cells of animals vaccinated with pcDNA3.1-FLK-1 or GFP
by i.p. injection of 1 mg rat anti-mouse monoclonal antibody to CD8 (ATCC,
CRL-1971) one day before VEGF pellet implantation.

Confocal microscopy
For immunofluorescence staining, eyes were frozen in optimum cutting
temperature (OCT) compound (Miles, Elkart, IN). Seven-micron-thick sections
were cut, air dried, and fixed in cold acetone for 10 min at −20°C. Nonspecific
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binding was blocked with 3% BSA-PBS-0.05% Tween 20 for 2 h at 37°C. For
detection of endothelial cells expressing VEGFR-2, the sections were incubated
with mixture of FITC-coupled monoclonal anti-mouse CD31 (0.5 µg/ml, BD
Pharmingen, San Diego, CA) and biotin-labeled anti-VEGFR-2 antibody (1 µg/ml,
R&D systems) in 1% BSA-PBS-0.05% Tween 20. For detection of both
endothelial and CD8+ T cells in the stroma, the sections were incubated with a
mixture of FITC-coupled monoclonal anti-mouse CD8 and biotin-labeled antiCD31 antibody (0.5 µg/ml, BD Pharmingen, San Diego, CA) in 1% BSA-PBS0.05% Tween 20. For detection of both CD8+ and CD4+ T cells, the sections were
incubated with a mixture of FITC-coupled monoclonal anti-mouse CD8 and
biotin-labeled anti-CD4 antibody (0.5 µg/ml, BD Pharmingen, San Diego, CA) in
1% BSA-PBS-0.05% Tween 20. After incubating overnight at 4°C, slides were
washed thoroughly in PBS, and streptavidin-conjugated Alexa Fluor 546 (1 µg/ml)
(Molecular Probes) in 1% BSA-PBS was added for 1 h at room temperature. Slides
were mounted with Vectashield without propidium iodide (Vector Laboratories,
Burlingame, CA). Images were captured with a Leica SP2 laser scanning confocal
microscope (Leica, Deerfield, IL).

Adoptive transfer of Thy1.1 CD8+ T cells
CD8+ T cells were isolated from FLK-1 based DNA immunized Thy 1.1+
C57BL/6.PL (H-2b) mice. Single-cell suspensions of pooled spleens were prepared
from immunized mice at day 7 after final immunization, and CD8+ T cells were
purified by incubating the splenocytes with biotin-conjugated anti-CD8 (15 µg/108
cells) mAb in PBS-2% FCS for 15 min at 4°C. Positive magnetic separation was
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then performed with LS+ columns (Miltenyi Biotec, Auburn, CA) according to the
suggested protocol. The purity of cells ranged from 90-95%. The purified Thy 1.1
CD8+ T cells (5 x 106 per mouse) were adoptively transferred into Thy 1.2 mice 24
h before virus ocular infection or VEGF pellet implantation.

Flow cytometric analysis
Single-cell suspensions were prepared from the SK cornea. Briefly, four corneas
per group were dissected, pooled together, and digested with 60 U/ml Liberase
(Roche Diagnostics) for 60 min at 37°C in a humidified atmosphere of 5% CO2.
After incubation, the corneas were disrupted by grinding with a syringe plunger on
a strainer (70 µm) and a single-cell suspension was made in complete RPMI 1640
medium. Next, the single-cell suspension obtained from corneal samples was
stained for FACS. Briefly, single cells were first blocked with an unconjugated
anti-CD32/CD16 mAb (0.5 µg/ml, BD Pharmingen, San Diego, CA) for 30 min in
FACS buffer and stained by anti-Thy 1.1-PerCP antibody (BD Pharmingen, San
Diego, CA) for 30 min. Finally, the cells were washed three times and samples
were acquired on a FACScan (BD Biosciences). The data were analyzed using the
CellQuest 3.1 software (BD Biosciences).

Statistical analysis
Significant differences between groups were evaluated by using the Student’s t test.
P < 0.05 was regarded as a significant difference between the two groups.
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RESULTS
VEGFR-2 is highly expressed in the neovessels of SK cornea
Previous studies on HSV-1 induced angiogenesis have identified VEGF as a
protein that is highly expressed in the infected cornea and clearly involved in HSV
specific angiogenesis (15). It has been known that VEGFR-2, one of the VEGF
receptors, is highly overexpressed in proliferating endothelial cells under
pathological conditions. To test whether this receptor is overexpressed in the HSV1 induced abnormal blood vessels, we observed VEGFR-2 expression in the
cornea after HSV-1 infection. Infection with 5 × 105 PFU of HSV-1 RE into the
scarified eye induced corneal inflammation and strong angiogenesis sprouted from
the limbal vessels, starting at day 3 after virus infection. To determine whether
VEGFR-2 is specifically expressed in the proliferating endothelial cells of SK
cornea, we stained the endothelial cells with fluorescein siothiocyanate (FITC)
antibody against CD31 (PECAM) and biotinylated antibody with streptavidinalexa fluor 546 against VEGFR-2. Microscopic observation revealed that
endothelial cells making up the newly grown blood vessels in the HSV infected
corneal stroma expressed CD31 as well as VEGFR-2 (Fig. 1). Thus, we could
confirm the idea that VEGFR-2 is highly expressed in the proliferating endothelial
cells of HSV infected cornea.

A FLK-1 encoded DNA immunization inhibits the severity of SK and HSV-1
induced angiogenesis
One essential step in the pathogenesis of SK is angiogenesis mediated by several
angiogenesis factors including the VEGF family of proteins. Thus, one explanation
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considered to explain the inhibitory effects on SK is antiangiogenesis. To evaluate
such an effect, we tested our hypothesis by demonstrating that an effective
antiangiogenic immune response was induced against HSV-1 RE corneal infection
by an orally administered DNA vaccine encoding murine FLK-1 or GFP as a
control carried by attenuated S. typhimurium. Protein expression of FLK-1 was
demonstrated by immunohistochemical staining by transfected Cos-7 cells (Fig.
2A). Gene transfer from attenuated S. typhimurium into Peyer’s patches by GFP
expression at 16 h after oral administration was demonstrated by confocal
microscopic observation (Fig. 2B).
To evaluate whether immunization with attenuated S. typhimurium
targeting FLK-1 inhibits the development of herpetic SK, mice were orally
administered with 108 CFU of attenuated S. typhimurium 3 times over a 4 week
period, at 2 week intervals. One week after final immunization, the corneas of
mice were scarified and infected with 5 × 105 HSV-1 RE. The levels of SK
severity and neovascularization were measured in the corneas by biomicroscopy in
groups of mice either pre-vaccinated with pcDNA3.1-FLK-1 or control GFP
plasmid prior to HSV infection. As shown in Fig. 3, significantly decreased
average SK severity and percentage of animals with clinical lesions were observed
in mice following immunization with the FLK-1-encoded DNA. A comparison of
average severity scores after day 4 p.i. were all significantly less in the FLK-1
DNA immunized than the control group (p < 0.05, 0.01). Furthermore, the results
shown in Fig. 3 indicate that levels of angiogenesis were significantly less at most
time points tested in the FLK-1 DNA compared to control plasmid immunized
animals (p < 0.01).
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FLK-1 specific CD8+ T cells are responsible for the antiangiogenic effects in
SK cornea
Previous studies on SK angiogenesis have shown that inhibited signaling of
VEGFRs highly expressed in angiogenic endothelial cells could reduce the
severity of SK (17). To evaluate whether immunization with FLK-1 encoded DNA
inhibits HSV-1 induced angiogenesis by FLK-1 specific immune cells, we
observed the SK cornea samples to reveal the localization of endothelial cells
targeting immune cells by confocal microscopy. Since it has been reported that
immunization with attenuated Salmonella encoding either non-self or self antigens
induces strong cytotoxic CD8+ T cell response (28, 33-35), we stained CD8+ T
cells with FITC and endothelial cells with biotinylated antibody against CD31 in
the SK cornea. Microscopic examination showed an association of infiltrated
CD8+ T cells with neovessels in the corneal stroma (SK day 21) of mice
immunized with FLK-1 DNA and infected with HSV-1 (Fig. 4). Almost no CD8+
T cells were observed in the cornea of control mice. To exclude the possibility of
non-specific staining of CD8 antibody to CD4+ T cells since many CD4+ T cells
infiltrate into the corneal stroma around 10 days after HSV infection, we stained
CD8+ T cells with FITC and CD4+ T cells with biotinylated antibody in the SK
cornea. As shown in Fig. 4, both CD8+ and CD4+ T cells were observed in the
cornea of animals immunized with FLK-1 DNA, but only CD4+ T cells were
found in the SK cornea of control group. These results suggest that FLK-1 specific
CD8+ T cells are responsible for the antiangiogenic effects in HSV-1 induced
angiogenesis.
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Inhibition

of

VEGF-induced

corneal

neovascularization

by

FLK-1

immunization
To test the antiangiogenic effects of FLK-1 DNA immunization in the eye, the
cornea of immunized mice were given 200 ng recombinant VEGF pellets using a
corneal micropocket assay method. In this experiment, immunization with FLK-1
DNA markedly inhibited (approximately 50% inhibition) the extent of VEGFinduced angiogenesis compared to control DNA treated animals at days 4 and 7
after pellet implantation (Fig. 5A and B).
To demonstrate the involvement of FLK-1 specific CD8+ T cells with
antiangiogenic response in the eye, CD8+ T cells were depleted before VEGF
pellet implantation. As shown in Fig. 5A and B, in vivo depletion of CD8+ T cells
resulted in the abrogation of the antiangiogenic response induced by FLK-1 DNA
immunization. This result demonstrates the antiangiogenic effects of CD8+ T cells
by FLK-1 DNA immunization.

Induction of T cell mediated lysis by FLK-1 DNA immunization
To test FLK-1 targeting CTL immune response, we measured FLK-1 specific
cytotoxicity against endothelial cell lines, which constitutively express VEGFR-2,
with 4 hours
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Cr-release assay using splenocytes from mice immunized with

FLK-1 DNA. One week after final immunization, splenocytes were collected from
mice immunized with FLK-1 or GFP DNA and coincubated with irradiated HEV
cells. After 5 days coincubation, CTL assay was performed with endothelial cell
lines. FLK-1 DNA immunization resulted in a significantly higher level of CTL
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responses against the endothelial cells expressing VEGFR-2, compared with
control immunization (Fig. 6A). However, neither immunization was effective in
evoking cytotoxicity against CT-26 cells not expressing FLK-1, indicating
VEGFR-2 specific lysis by FLK-1 immunization (Fig. 6B). In addition, neither
vaccination induce cytotoxicity against YAC cells, which are specific cell lines for
NK cell cytotoxicity, excluding direct lysis by NK cells (Fig. 6C).

Adoptive transfer of FLK-1 specific CD8+ T cells efficiently inhibits
angiogenesis
To further establish the role of FLK-1 specific CD8+ T cells in suppressing corneal
angiogenesis, an adoptive transfer system was used. CD8+ T cells were isolated
from FLK-1 based DNA immunized Thy 1.1+ C57BL/6.PL (H-2b) mice and
transferred into Thy 1.2 recipients. Mice were then infected ocularly with HSV-1
or implanted with VEGF pellets into the cornea to induce angiogenesis. The results
expressed in Fig. 7A and B indicate that the severity of lesions and extent of
angiogenesis induced by HSV infection or VEGF pellet implantation were reduced
if animals received CD8+ T cells of FLK-1 based DNA immunized mice. To
reveal the localization of adoptive transferred Thy 1.1+ CD8+ T cells in the SK
cornea, we stained Thy 1.1+ cells with biotinylated antibody against Thy 1.1 and
endothelial cells with FITC against CD31. Microscopic observation showed
infiltration of few Thy 1.1+ cells near neovessels in the cornea stroma of mice
adoptively transferred with Thy 1.1+ CD8+ T cells of FLK-1 based DNA
immunized mice. Almost no Thy 1.1+ cells were observed in the cornea of mice
adoptively transferred with Thy 1.1+ CD8+ T cells of control DNA immunized
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mice (Fig. 7C). In addition, at day 14 p.i. flow cytometry analysis revealed a 3 fold
increase in the number of Thy 1.1+ cells per cornea of mice adoptively transferred
with Thy 1.1+ CD8+ T cells of FLK-1 based DNA immunized mice than the
control eye (Fig. 7D).

DISCUSSION
Our study shows that oral immunization with attenuated S. typhimurium carrying
FLK-1 gene results in reduced SK severity by inhibition of ocular angiogenesis.
Antiangiogenic effects of FLK-1 DNA immunization were caused by induction of
cytotoxic CD8+ T cells against FLK-1. Previously, our studies have demonstrated
that VEGF, one of the major angiogenic factors induced by HSV-1 ocular
infection, plays an essential role in the formation of neovessels induced by
inflammation in the normally avascular cornea (15, 16). Additionally, various
proinflammatory cytokines and chemokines are overexpressed by HSV infection
and these released molecules in inflammatory cornea subsequently induce the
expression of VEGF directly or indirectly. For example, it was reported that IL-1
and IL-6 are upregulated in the cornea by HSV infection and then these cytokines
induce VEGF expression in vitro and in vivo (15, 16, 20, 21, 25). CXC
chemokines such as MIP-2 or KC (CXCL3) were also produced by viral
stimulation and these chemokines induce recruitment of polymorphonuclear
leukocytes (PMN), one of major inflammatory cells producing VEGF, into the SK
cornea (36, 37). Furthermore, CpG motifs of HSV DNA directly induce VEGF
expression from inflammatory cells (24). Accordingly, various antiangiogenic
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strategies targeting VEGF family genes including VEGF and its receptors could
successfully diminish immunoinflammatory SK lesions (16, 17).
Although it seems that VEGF is the major molecule as a final trigger of
HSV-1 induced angiogenesis, knock down of VEGF may not completely inhibit
pathological angiogenesis. Since angiogenesis is a complicated process in the
cornea during HSV infection, we assume that VEGF is not the sole mediator
responsible for the HSV induced angiogenesis in the cornea. Possibly, other
angiogenic molecules such as fibroblast growth factor-2 (FGF-2) may be involved
in this process without relation to VEGF molecules. Therefore approaches that
target pathological blood vessels might be an attractive strategy for antiangiogenic
therapy. In response to angiogenic molecules, newly formed blood vessels express
various angiogenic receptors and integrins (38, 39). Among these surface
molecules, VEGFR-2 is highly overexpressed on the cell surface of activated and
proliferating endothelial cells under pathological conditions (27, 28). This finding
suggests that control of VEGFR-2 expressing endothelial cell growth may be an
efficient approach for the treatment of neovascular disease causing unwanted
angiogenesis. Accordingly, various immunotherapeutic strategies targeting
VEGFR-2 of uncontrolled endothelial cells have been suggested by investigators
mainly for the purpose of inhibition of tumor progression and angiogenesis (28-31,
33, 34). Interestingly, although VEGFR-2 is autologous, our vaccination strategy,
as well as those that have been previously introduced, could efficiently break
peripheral T-cell tolerance against self-antigen, VEGFR-2 (28, 30, 33, 34). The
precise mechanism by which oral DNA vaccination targeting self-antigen exerts
immune response remains unresolved and this issue is under further investigation.
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Induction of CTL responses against FLK-1 by oral immunization
demonstrates that FLK-1 specific CD8+ T cells might kill or control the
proliferating endothelial cells, leading to reduced angiogenesis and subsequently
diminished SK lesions. We could further show that angiogenesis induced by
VEGF pellet implantation was inhibited in the immunized mice. To demonstrate
involvement of CD8+ T cells in antiangiogenic immune response, neutralizing
antibody to deplete CD8+ T cells was used. As was expected, depletion of CD8+ T
cells abrogated the antiangiogenic activity in the immunized and VEGF pellet
implanted mice. However, this method could not be used in herpetic SK model
since HSV-1 infected mice without CD8+ T cells might induce severe encephalitis
caused by virus spread into the central nervous system. Thus we used the adoptive
transfer system in the SK model to demonstrate the antiangiogenic immune
activity of CD8+ T cells. Finally, the adoptive transfer of CD8+ T cells collected
from immunized mice into non-immunized and HSV infected mice could
efficiently reduce clinical SK lesions by antiangiogenic immune response. Our
data again support the idea that FLK-1 specific CD8+ T cells demonstrate an
angiostatic function and show this activity in the SK model.
In summary, we demonstrated that oral immunization with attenuated S.
typhimurium harboring murine FLK-1 could break peripheral T cell tolerance and
induce CTL against self-antigen VEGFR-2. This FLK-1 specific immune response
resulted in reduction of herpetic SK lesion severity by its antiangiogenic effects.
This novel approach may represent a novel therapeutic strategy for herpetic SK as
well as neovascular diseases.
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Figure 1. Expression of VEGFR-2 on the proliferating endothelial cells of
neovessels of SK cornea.
The mice were scarified lightly on their corneas with a 32 gauge needle and
infected with a 2 µl drop containing 5 × 105 PFU of HSV-1 RE that was applied to
the eye. At day 21 post infection, eyes were frozen and seven-micron-thick
sections were cut, air dried, and processed for immunofluorescences staining as
described in materials and methods. Briefly, for detection of endothelial cells
expressing VEGFR-2, the sections were incubated with a mixture of FITC-coupled
monoclonal anti-mouse CD31 (0.5 µg/ml) and a biotin-labeled anti-VEGFR-2
antibody (1 µg/ml). On the next day, slides were incubated with streptavidinconjugated Alexa Fluor 546 (1 µg/ml). Slides were mounted with Vectashield
without propidium iodide. Images were captured with a Leica SP2 laser scanning
confocal microscope. The white arrows indicate the cross section of endothelial
cells expressing CD31 as well as VEGFR-2, lining the lumen of a blood vessel in
the corneal stroma.
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Figure 2. Functionality of FLK-1 expression and gene transfer from attenuated
salmonella typhimurium to Peyer’s patches.
FLK-1 expression was verified by immunohistochemical staining by transfected
Cos-7 cells. The black arrows indicate the cells expressing FLK-1 protein (A).
Gene transfer from attenuated S. typhimurium into Peyer’s patches by GFP
expression at 16 h after oral administration was demonstrated by confocal
microscopic observation. The white arrows indicate the cells expressing GFP
transferred from attenuated S. typhimurium based GFP DNA (B).
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Figure 3. Inhibition of SK lesion severity, incidence, and HSV-induced
angiogenesis by FLK-1 DNA immunization.
Groups of animals (n = 6) were orally administered with 108 CFU of attenuated S.
typhimurium 3 times over a 4 week period, at 2 week intervals. One week after
final immunization, the corneas were scarified and infected with 5 × 105 HSV-1
RE. The levels of SK severity and neovascularization were measured in the
corneas by biomicroscopy in groups of mice either pre-vaccinated with
pcDNA3.1-FLK-1 (ο) or control GFP (•) plasmid prior to HSV infection. The data
are compiled from three independent experiments. Statistically significant
differences in SK and angiogenic score were observed between the groups (* p <
0.05, ** p < 0.01). Images were taken by stereomicroscopic imaging system at day
21 after virus infection (original magnification, × 40)
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Figure 4. Involvement of FLK-1 specific CD8+ T cells for the antiangiogenic
effects in SK cornea.
Upper panels depict the localization of CD8+ T cells (FITC, Green) and
endothelial cells (Biotin + Alexa, Red) in the corneal stroma (SK day 21) of mice
immunized and infected with HSV-1. Lower panels depict the infiltration of CD8+
(FITC, Green) and CD4+ (Biotin + Alexa, Red) T cells in the SK (day 10) cornea
of mice immunized and infected with HSV-1. The white arrows indicate the
infiltrated CD8+ T cells in the corneal stroma.
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Figure 5. Inhibition of VEGF-induced corneal angiogenesis by FLK-1
immunization.
The cornea of mice (n = 6) immunized with either attenuated S. typhimurium
harboring pcDNA3.1-FLK-1 or -GFP was given 200 ng recombinant VEGF pellets
(*) using a corneal micropocket assay method. Furthermore, to demonstrate the
involvement of FLK-1 specific CD8+ T cells with antiangiogenic response in the
eye, CD8+ T cells of immunized mice were depleted before VEGF pellet
implantation. The angiogenesis area (A) was measured on days 4 and 7 after the
VEGF pellet implantation. Images were taken by stereomicroscopic imaging
system at day 4 after VEGF pellet implantation (original magnification, × 40) (B).
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Figure 6. Specific lysis of endothelial cells by FLK-1 specific CD8+ T cells.
Splenocytes from FLK-1 or GFP DNA immunized mice were collected and
coincubated with irradiated HEV, CT-26, or YAC cells. After 5 days coincubation,
the activated T cells were harvested and tested for cytotoxicity.
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Figure 7. Inhibition of angiogenesis by adoptive transfer of FLK-1 specific
CD8+ T cells.
CD8+ T cells were isolated from FLK-1 based DNA immunized Thy 1.1+
C57BL/6.PL (H-2b) mice (n = 4) and transferred into Thy 1.2 recipients. Mice (n =
6) were then infected ocularly with HSV-1 RE or implanted with VEGF (200 ng)
pellets into the cornea to induce angiogenesis. The levels of SK severity and
neovascularization (A) or angiogenic area (B) were measured in the corneas by
biomicroscopy in groups of mice that received CD8+ T cells of FLK-1 (ο) or
EGFP (•) based DNA immunized mice. Statistically significant differences in SK
and angiogenic score were observed between the groups (* p < 0.05, ** p < 0.01).
The localization of adoptive transferred Thy 1.1+ CD8+ T cells (Biotin+Alexa,
Red) and endothelial cells (FITC, Green) in the SK cornea is depicted. The white
arrow indicates the infiltrated Thy 1.1+ CD8+ T cells around endothelial cells in the
corneal stroma (C). Four corneas of mice of each group were pooled together and
the number of Thy 1.1+ cells was enumerated by FACS analysis as described in
materials and methods. The number in the right corner represents the percentage of
Thy 1.1+ cells (D).
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